WO2008084081A2 - 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders - Google Patents

2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders Download PDF

Info

Publication number
WO2008084081A2
WO2008084081A2 PCT/EP2008/050253 EP2008050253W WO2008084081A2 WO 2008084081 A2 WO2008084081 A2 WO 2008084081A2 EP 2008050253 W EP2008050253 W EP 2008050253W WO 2008084081 A2 WO2008084081 A2 WO 2008084081A2
Authority
WO
WIPO (PCT)
Prior art keywords
cio
cyano
compounds
alkyl
methyl
Prior art date
Application number
PCT/EP2008/050253
Other languages
French (fr)
Other versions
WO2008084081A3 (en
Inventor
Barbara Nave
Sven Harmsen
Bernd Müller
Thomas Grote
Original Assignee
Basf Se
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Se filed Critical Basf Se
Publication of WO2008084081A2 publication Critical patent/WO2008084081A2/en
Publication of WO2008084081A3 publication Critical patent/WO2008084081A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Definitions

  • the present invention relates to 2-substituted pyrimidines of the formula I
  • R 1 is C2-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, C3-Ci2-cycloalkyl, C 4 -Ci o- cycloalkenyl, phenyl or a five- to ten-membered saturated, partially unsaturated or aromatic heterocycle which is attached via carbon and which contains one, two, three or four heteroatoms selected from the group consisting of O, N and S; where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of R 1 for their part may be partially or fully halogenated or may carry one, two, three or four radicals R v , which may be the same or different from each other:
  • R v is phenyl, where the phenyl moiety may carry one, two or three radicals which may be the same or different from each other and which are selected from the group consisting of: halogen, Ci-C ⁇ -alkyl,
  • n O, 1 or 2;
  • a 1 , A 2 , A 3 , A and A' independently of one another are hydrogen, C-i-C ⁇ - alkyl, C 2 -C 6 -alkenyl, C 2 -C 6 -alkynyl, C 3 -C 8 -cycloalkyl, C 3 -C 8 - cycloalkenyl or phenyl, where the organic radicals may be partially or fully halogenated or may be substituted by halogen, nitro, cyanato, cyano and/or Ci-C4-alkoxy; or A 1 and A 2 , or A and A', respectively, together with the atoms to which they are attached are a five- or six- membered saturated, partially unsaturated or aromatic heterocycle which comprises one, two, three or four heteroatoms selected from the group consisting of O, N and S;
  • R 2 is halogen, cyano, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Cs-C ⁇ -cycloalkyl, Ci-C4-alkoxy, C3-C4-alkenyloxy, C3-C4-alkynyloxy, d-C ⁇ -alkylthio, di-(Ci-C6- alkyl)amino or Ci-C ⁇ -alkylamino, where the aliphatic and/or alicyclic groups of the radical definitions of R 2 for their part may be partially or fully halogenated or may carry one, two, three or four radicals R u , which may be the same or different from each other:
  • R u is halogen, cyano, Ci-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, hydroxyl,
  • q O, 1 or 2;
  • a 4 , A 5 and A 6 independently of one another have the meanings of A 1 , A 2 and A 3 as defined above;
  • R u aliphatic, alicyclic and/or aromatic groups of the radical definitions of R u for their part may be partially or fully halogenated or may carry one, two or three radicals R ua , which may be the same or different from each other and which have the meanings of R u as defined above;
  • Z is O, S, NR a1 , NOR a1 or N-NR z1 R c1 ;
  • R a , R a1 , R b , R c , R c1 independently of one another are hydrogen, Ci-C ⁇ - alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Cs-C ⁇ -cycloalkyl or C4-C6-cycloalkenyl;
  • R b1 has the meanings of R b as defined above, except for hydrogen;
  • R z , R z1 independently of one another have the meanings of R a as defined above and may additionally be -CO-R a2 , where R a2 has the meanings of R a as defined above;
  • R a , R a1 , R b , R b1 , R c , R c1 , R z and R z1 for their part may be partially or fully halogenated or may carry one, two, three or four groups R 1 , which may be the same or different from each other:
  • R 1 is halogen, cyano, Ci-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, d-C ⁇ -alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-C ⁇ -cycloalkyl, Cs-C ⁇ -cycloalkenyl,
  • R a , R a1 , R b , R b1 , R c , R c1 , R z or R z1 together with the atoms, to which they are attached, may form a five-, six- or seven-membered saturated, partially unsaturated or aromatic heterocycle which comprises one, two, three or four heteroatoms selected from the group consisting of O, N and S;
  • x is O or i ;
  • R e , R f , R9, R e# independently of one another are hydrogen, d-C ⁇ -alkyl, C2-Cs-alkenyl, C2-Cs-alkynyl, Cs-C ⁇ -cycloalkyl, C4-C6-cycloalkenyl,
  • Q is oxygen or N-R e# ;
  • Q' is C(H)-R k , C-R k , N-N(H)-R e# or N-R e# ; 1 ⁇ - may be a double bond or a single bond;
  • R h , R k have the same meanings as R e and may additionally be halogen or cyano; or
  • R h together with the carbon to which it is attached may be a carbonyl group
  • R e , R e# , R f , R9, R h or R k may be partially or fully halogenated or may carry one to four groups R w , which may be the same or different from each other:
  • R w is halogen, cyano, Ci-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, d-C ⁇ -alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-C ⁇ -cycloalkyl, C3-C6-cycloalkenyl, Cs-C ⁇ -cycloalkoxy, Cs-C ⁇ -cycloalkenyloxy, and where two of the radicals R f , Rs, R e or R e# together with the atoms to which they are attached may form a five- or six-membered saturated, partially unsaturated or aromatic heterocycle which contains one to four heteroatoms from the group consisting of O, N and S.
  • n 1 , 2, 3, 4 or 5;
  • p 0, 1 or 2;
  • a 10 , A 11 , A 12 independently of one another have the meanings of A 1 , A 2 and A 3 as defined above;
  • L may be identical or different from each other and where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of L for their part may be partially or fully halogenated or may carry one, two, three or four radicals R L , which may be the same or different from each other:
  • s 0, 1 or 2;
  • a 13 , A 14 and A 15 independently of one another have the meanings of A 1 , A 2 and A 3 as defined above;
  • R L aliphatic, alicyclic and/or aromatic groups of the radical definitions of R L for their part may be partially or fully halogenated or may carry one, two, three or four groups R LA , which may be the same or different from each other and which have the meanings of R L as defined above;
  • the invention also relates to pharmaceutical compositions comprising a 2-substituted pyrimidine of the formula I as defined herein or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier. Moreover the invention relates to the use of a 2-substituted pyrimidine of the formula I as defined herein and of their pharmaceutically acceptable salts in the manufacture of a medicament in particular a medicament for therapy or treatment of cancer or a cancerous disease, respectively. The invention also provides a method for cancer treatment, which comprises administering to the subject in need thereof an effective amount of a 2-substituted pyrimidine of the formula I as defined herein or of their pharmaceutically acceptable salts.
  • cancer is still one of the leading causes of death.
  • cancer is the 2 nd most common reproductive cancer after breast cancer in women.
  • a large number of cytotoxic compounds are known to effectively inhibit the growth of tumor cells, including taxoides like paclitaxel (Taxole), docetaxel (Taxotere), the vinka alkaloids vinorelbine, vinblastine, vindesine and vincristine.
  • Taxoides like paclitaxel (Taxole), docetaxel (Taxotere), the vinka alkaloids vinorelbine, vinblastine, vindesine and vincristine.
  • these compounds are natural products having a complex structure and thus are difficult to produce.
  • EP-A 715 851 discribes pharmacologically active 5-phenylpyrimidines which may carry, among other substituents, a piperazine or morpholine radical or an amino group which is mono- or disubstituted by alkyl and/or aryl in the 2-position, and which, among other radicals may carry an alkyl radical or certain substituted alkyl radicals in the 4-position
  • WO 2005/030216 describes pharmacologically active 5-phenylpyrimidines which carry an aryl, heteroaryl or a substituted amino group in the 2-position and a secondary amino group or cycloalkyl group in the 4-position.
  • the compounds are mentioned to be usefull as anticancer agents.
  • WO 2006/079556 teaches 5-phenylpyrimidines which carry a substituted amino or alkoxy radical in the 4-postion and further radicals in the 2- and 6-positions of the pyrimidine ring to be useful in anticancer therapy.
  • an object of the present invention to provide compounds which effectively control or inhibit growth and/or progeny of tumor cells and thus are useful in the treatment of cancer. It is highly desirable that these compounds can be synthesized from simple starting compounds according to standard methods of organic chemistry.
  • 2-Substituted pyrimidines of the formula I have been described in WO 2004/087678.
  • the compounds disclosed therein are active against various phytopathogenic fungi.
  • these documents do not describe or suggest that these compounds may be effective in the treatment of diseases or even in the treatment of cancer.
  • 2-Substituted pyrimidines I can be prepared by the methods disclosed in WO 2004/087678 as well as by analogy to the methods described in WO 2004/103978 and in the literature cited therein as well as by standard methods of organic chemistry.
  • physiologically tolerated salts of the 2-substituted pyrimidines I especially acid addition salts with physiologically tolerated acids.
  • suitable physiologically tolerated organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, organic sulfonic acids having from 1 to 12 carbon atoms, e.g.
  • Ci-C4-alkylsulfonic acids such as methanesulfonic acid, cycloaliphatic sulfonic acids such as S-(+)-10-camphorsulfonic acids and aromatic sulfonic acids such as benzenesulfonic acid and toluenesulfonic acid, di- and tricarboxylic acids and hydroxycarboxylic acids having from 2 to 10 carbon atoms such as oxalic acid, malonic acid, maleic acid, fumaric acid, mucic acid, lactic acid, tartaric acid, citric acid, glycolic acid and adipic acid, as well as cis- and trans- cinnamic acid, furoic acid and benzoic acid.
  • the physiologically tolerated salts of 2-substituted pyrimidines I may be present as the mono-, bis-, tris- and tetrakis-salts, that is, they may contain 1 , 2, 3 or 4 of the aforementioned acid molecules per molecule of formula I.
  • the acid molecules may be present in their acidic form or as an anion.
  • the acid addition salts are prepared in a customary manner by mixing the free base of a 2-substituted pyrimidine I with a corresponding acid, where appropriate in solution in water or an organic solvent as for example a lower alcohol such as methanol, ethanol, n-propanol or isopropanol, an ether such as methyl tert-butyl ether or diisopropyl ether, a ketone such as acetone or methyl ethyl ketone, or an ester such as ethyl acetate.
  • Solvents, wherein the acid addition salt of I is insoluble (anti-solvents) might be added to precipitate the salt.
  • Suitable anti-solvents comprise C1-C4- alkylesters of Ci-C4-aliphatic acids such as ethyl acetate, aliphatic and cycloaliphatic hydrocarbons such as hexane, cyclohexane, heptane, etc., di-Ci-C4-alkylethers such as methyl tert-butyl ether or diisopropyl ether.
  • - halogen fluorine, chlorine, bromine or iodine, in particular chlorine or fluorine;
  • alkenyl and the alkenyl moieties of alkenyloxy unsaturated, straight-chain or branched hydrocarbon radicals having 2 to 10, preferably 2 to 6, and in particular 2 to 4 carbon atoms, and a double bond in any position, especially C3-C4-alkenyl, for example ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl,
  • - alkadienyl unsaturated straight-chain or branched hydrocarbon radicals having 4 to 8, in particular 4 to 6 carbon atoms and two double bonds in any position, for example butadiene, 1 ,3-pentadiene, 1 ,4-pentadiene, 1 ,3-hexadiene, 1 ,4-hexadiene and 1 ,5-hexadiene;
  • - alkynyl straight-chain or branched hydrocarbon radicals having 2 to 10, preferably 2 to 6, in particular 2 to 4 carbon atoms, and a triple bond in any position, especially C3-C4-alkynyl, for example ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-1-butynyl, 1 ,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl
  • - cycloalkyl mono- or bicyclic hydrocarbon radicals having 3 to 10 carbon atoms; monocyclic groups having 3 to 8, especially 3 to 6 ring members, for example C3-C8-cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;
  • haloalkyl and the haloalkyl moieties of haloalkoxy straight-chain or branched alkyl groups having 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, especially 1 to 4 carbon atoms (as mentioned above), where the hydrogen atoms in these groups may be partially or fully replaced by halogen atoms as mentioned above, for example Ci-C4-haloalkyl, such as chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl,
  • - oxy-alkyleneoxy divalent straight-chain hydrocarbon radicals having 2 to 3 carbon atoms, e.g. OCH 2 CH 2 O or OCH 2 CH 2 CH 2 O;
  • heterocycle homo- or bicyclic hydrocarbon radicals containing one to four heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom; unsaturated (heterocyclyl) includes partially unsaturated, e.g. mono-unsaturated, and aromatic (heteroaryl); said heterocycles in particular include:
  • 5-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom
  • 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom as ring members, for example 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, thiophenyl, 2-pyrrolyl, 3-pyrrolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-imidazolyl, 4-imidazolyl, 1 ,2,4
  • 6-membered heteroaryl containing one to four nitrogen atoms: 6-membered heteroaryl groups which, in addition to carbon atoms, may contain one to three or one to four nitrogen atoms as ring members, for example 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-py ⁇ idazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 1 ,2,3-triazinyl, 1 ,3,5-triazin-2-yl and 1 ,2,4-triazin-3-yl.
  • 9- or 10-membered heteroaryl containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom: 9- or 10-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom as ring members, in particular benzo-fused 5- or 6-membered heteroaryl which contains one to three nitrogen atoms or one nitrogen atom and one oxygen or sulfur atom (i. e.
  • 5- or 6-membered heteroaryl groups which, in addition to carbon atoms, contain one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom as ring members and in which two adjacent carbon ring members or one nitrogen and one adjacent carbon ring member may be bridged by a buta-1 ,3-dien-1 ,4-diyl group), for example benzothiazol-2-yl, 1 H-indol-1-yl, 1 H-indol-2-yl, 1 H-indol-3-yl, 1 H-indazol-1-yl, 1 H-indazol-2-yl, benzofuran- 2-yl and benzofuran-3-yl; quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, phthalazinyl, quinoxalinyl, quina
  • the scope of the present invention includes the (R) and (S) isomers of the formula I having chiral centers.
  • any mixture of the (R) and (S) isomer compounds in any ratio including the racemates is also within the scope of the present invention.
  • R 1 is different from C3-Cio-cycloalkyl or C3-Cio-cycloalkenyl.
  • R 1 is C2-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, where the aliphatic groups of the radical definitions of R 1 for their part may be unsubstituted, partially or fully halogenated or may carry one, two, three or four radicals R v which may be the same or different from each other:
  • R 1 is C2-C8-alkyl, C2-C8-haloalkyl, C2-C8-alkenyl, C2-C8-haloalkenyl, C2-Cs-alkynyl or C2-C8-haloalkynyl, more particularly d-Cs-alkyl, Ci-Cs-haloalkyl, d-Cs-alkenyl or C2-C8-haloalkenyl, where the aliphatic groups may carry one or two, especially one radical(s) R v which may be the same or different from each other and which are preferably selected from the group consisting of Ci-C ⁇ -alkyl, d-drhaloalkyl, hydroxyl, Ci-C ⁇ -alkoxy, C3-C6- cycloalkyl, d.-drhalocycloalkyl, and phenyl, where the phenyl moiety may carry one
  • radicals R v are selected from the group consisting of hydroxyl and d-C ⁇ -alkoxy, preferably hydroxyl and d-d-alkoxy such as methoxy, ethoxy, propoxy and butoxy.
  • a preferred embodiment of the invention relates to 2-substituted pyrimidines I, wherein R 1 is linear C 2 -C 8 -alkyl or C 2 -C 8 -haloalkyl, i.e. n-C 2 -C 8 -alkyl or n-C 2 -C 8 -haloalkyl, preferably n-C2-C6-alkyl and more preferably n-C2-d-alkyl, i. e. where the chain of carbon atoms of the alkyl radical is not branched but linear, e. g. ethyl, n-propyl and n-butyl, particularly methyl and ethyl.
  • a more preferred embodiment of the invention relates to 2-substituted pyrimidines I wherein R 1 is d-Cs-alkyl or d-Cs-haloalkyl, preferably d-C ⁇ -alkyl, which in each case is branched but preferably not branched in the ⁇ -position (e. g. branched in the ⁇ - or ⁇ -position), and which is unsubstituted or may carry one or two, especially one radical R v selected from the group consisting of hydroxyl and d-d-alkoxy such as methoxy or ethoxy, e. g.
  • R 1 is branched or carries a halogen atom or a subsitutend R v , R 1 may have a center of chirality. If R 1 carries a halogen atom creating a center of chirality, the (S)-isomers are preferred for these groups. In the case of halogen-free alkyl or alkenyl groups having a center of chirality in R 1 , preference is given to the (R)-configured isomers.
  • substituent(s) from the group consisting of halogen, d-C ⁇ -alkyl, d-C ⁇ -haloalkyl and oxy-Ci-C3-alkyleneoxy, in particular halogen, d-C ⁇ -alkyl and C-i-C ⁇ -haloalkyl.
  • R 1 is a saturated or unsaturated, preferably saturated five- or six-membered C-bound heterocycle which carries an oxygen atom or a nitrogen atom or an amino -(-N(R X )- group as ring member, examples including tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl and piperidinyl, e. g. pyrrolidin-2-yl and piperidin-2-yl, and which may carry one or two Ci-C ⁇ -alkyl, preferably Ci-C4-alkyl substituents, e. g.
  • 2-substituted pyrimidines I in which R 2 is halogen, cyano, C1-C4- alkyl, Ci-C4-haloalkyl or Ci-C4-alkoxy, in particular fluorine, chlorine, bromine, methyl, cyano, methoxy or ethoxy, more preferably fluorine, chlorine, cyano, methyl or methoxy.
  • R 2 is chlorine, cyano or methyl.
  • R a , R a1 , R b , R c and R c1 independently of one another are hydrogen, d-C ⁇ -alkyl, d-C ⁇ -haloalkyl, C2-C6- alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, C2-C6-haloalkynyl, C 3 -C6-cycloalkyl, C3-C6- halocycloalkyl, C4-C6-cycloalkenyl or C4-C6-halocycloalkenyl, more preferably hydrogen, Ci-C4-alkyl, Ci-C4-haloalkyl, C2-C4-alkenyl, C2-C4-alkynyl or C 3 -C6- cycloalkyl, especially hydrogen or Ci-C4-alkyl.
  • those compounds I are preferred where R b1 has the preferred meanings of R b as defined above, except for hydrogen.
  • those compounds I are preferred where R z and R z1 independently of one another have the preferred meanings of R a as defined above or are -CO-R a2 , where R a2 has the preferred meanings of R a as defined above.
  • R a and R a1 independently of one another are hydrogen or Ci-C4-alkyl, especially Ci-C2-alkyl, e. g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl. More preferably R a is hydrogen, methyl, ethyl, n-propyl or iso-propyl. Likewise, more preferably R a1 is methyl. Furthermore, those compounds I are more particularly preferred where R b is hydrogen or Ci-C4-alkyl, especially Ci-C2-alkyl, e. g.
  • R b is hydrogen or methyl.
  • R z is hydrogen, Ci-C4-alkyl, e. g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, in particular methyl, or -CO-R a2 , where R a2 is Ci-C4-alkyl, e. g. methyl or ethyl, in particular methyl. More preferably R z is hydrogen, methyl or -CO-R a2 , and R a2 is methyl.
  • R a1 is hydrogen or Ci-C4-alkyl, especially Ci-C2-alkyl, in particular methyl.
  • R a and/or R b especially both R a and R b are hydrogen.
  • R 3 is pyrrolidin-2-on-1-yl, piperidin-2-on-1-yl, azepin-2-on1-yl, pyrrolidin-2-thion-1-yl, piperidin-2-thion-1-yl or azepin-2-thion-1-yl.
  • radical R 3 is a radical of the formulae R 3a or R 3b as defined above.
  • radical R 3b corresponds one of the following formulae:
  • R e# , Rs and R h are as defined above.
  • R e# , R 9 and R h are preferably independently of one another hydrogen, d-C ⁇ -alkyl, C 2 -C6-alkenyl,
  • R e# , Rs and R h are as defined above.
  • R e# , Rs and R h are as defined above.
  • examples for these radicals include radicals of the following formulae:
  • R e , R f and Rs are as deffned above.
  • Q is oxygen.
  • Q is oxygen and R e and R h are H or d-C ⁇ -alkyl.
  • R 3a examples include:
  • substituents L 1 to L 5 are independently of each other selected from the group consisting of:
  • Ci-Cs-alkyl in particular d-C ⁇ -alkyl, especially Ci-C4-alkyl, such as methyl, ethyl, propyl and butyl, preferably methyl; C2-Cio-alkenyl, in particular
  • C2-C6-alkenyl especially C2-C4-alkenyl, such as ethenyl, propenyl and butenyl;
  • C2-Cio-alkynyl in particular C2-C6-alkynyl, especially C2-C4-alkynyl, such as ethynyl, propynyl and butynyl;
  • d-C ⁇ -alkoxy in particular Ci-C4-alkoxy, preferably methoxy and ethoxy;
  • a 10 , A 11 independently of one another are hydrogen, Ci-C ⁇ -alkyl, C 2 -C ⁇ - alkenyl, C 2 -C6-alkynyl, C 3 -C8-cycloalkyl or phenyl, where the organic radicals may be partially or fully halogenated or may be substituted by halogen, cyano and/or Ci-C 4 -alkoxy; or A 10 and A 11 together with the atoms to which they are attached are a five- or six-membered saturated heterocycle which comprises one or two heteroatoms from the group consisting of O, N and S;
  • L may be partially or fully halogenated, e. g. where L may be C-i-C ⁇ - haloalkyl, especially Ci-C 2 -fluoroalkyl, such as trifluoromethyl.
  • n is preferably 1 , 2 or 3.
  • 2-substituted pyrimidines I wherein one or two radical(s) L is (are) attached to one (or two) of the ortho-position(s) of the phenyl ring system.
  • 2-substituted pyrimidines I wherein n is 1 , 2 or 3, i. e. the phenyl ring attached to the pyrimidine skeleton carries 1 , 2 or 3 substituents R L which are different from hydrogen.
  • L 1 is fluorine, chlorine, CH3 or CF3, more preferably fluorine or chlorine;
  • L 2 , L 4 independently of one another are hydrogen, CH3 or fluorine, more preferably hydrogen;
  • L 5 is hydrogen, fluorine, chlorine or CH 3 , more preferably fluorine or chlorine.
  • R 1 is C 2 -Cio-alkyl, C 2 -Cio-alkenyl or C 2 -Cio-alkynyl, where the aliphatic groups of the radical definitions of R 1 for their part may be partially or fully halogenated or may carry one, two, three or four radicals R v which may be the same or different from each other:
  • R 2 is halogen, cyano, Ci-C4-alkyl, Ci-C4-alkoxy or Ci-C4-haloalkyl;
  • R 3 has the meanings given in claim 1 but does not carry any group R wa ;
  • n 1 , 2 or 3 where at least one substituent L is located in the ortho-position on the phenyl ring and wherein L are identical or different and selected from the group consisting of:
  • a 10 , A 11 independently of one another are hydrogen, d-C ⁇ -alkyl, C2-C6- alkenyl, C2-C6-alkynyl, C 3 -C8-cycloalkyl or phenyl, where the organic radicals may be partially or fully halogenated or may be substituted by halogen, cyano and/or Ci-C4-alkoxy; or A 10 and A 11 together with the atoms to which they are attached are a five- or six-membered partially unsaturated or aromatic heterocycle which comprises one, two, three or four heteroatoms selected from the group consisting of O, N and S;
  • aliphatic, alicyclic and/or aromatic groups of the radical definitions of L for their part may be partially or fully halogenated or may carry one, two, three or four radicals R L , which may be the same or different from each other.
  • n 1 , 2 or 3, where at least one substituent L is located in the ortho-position on the phenyl ring;
  • R 1 is C 4 -C8-alkyl or C 4 -C8-haloalkyl, preferably C 4 -C6-alkyl, which in each case is branched but preferably not branched in the ⁇ -position (e. g. branched in the ⁇ - or ⁇ -position), and which is unsubstituted or may carry one or two, especially one radical R v selected from the group consisting of hydroxyl and Ci-C 4 -alkoxy such as methoxy or ethoxy, e. g.
  • R 2 is halogen, cyano, Ci-C 4 -alkyl, Ci-C 4 -alkoxy or Ci-C 4 -haloalkyl, in particular chlorine, fluorine, cyano, methyl, ethyl, methoxy or ethoxy;
  • n 1 , 2 or 3, where at least one substituent L is located in the ortho-position on the phenyl ring;
  • R 1 is C 2 -Cs-alkenyl or C 2 -C8-haloalkenyl, preferably C 2 -C8-alkenyl, e. g. but-1-en-4-yl
  • but-3-en-1-yl but-2-en-1-yl, 2-methyl-but-1-enyl, 3-methyl-but-1-enyl, 2- methyl-but-2-en-1-yl and 3-methyl-but-2-en-1-yl, more preferably but-1-en-4-yl and 3-methyl-but-1-enyl;
  • R 2 is halogen, cyano, Ci-C4-alkyl, Ci-C4-alkoxy or Ci-C4-haloalkyl, in particular chlorine, fluorine, cyano, methyl, ethyl, methoxy or ethoxy;
  • n 1 , 2 or 3, where at least one substituent L is located in the ortho-position on the phenyl ring;
  • R 1 selected from cyclopentyl, cyclohexyl, pyrrolidin-2-yl and piperidin-2-yl, and which may carry one or two d-C ⁇ -alkyl, preferably Ci-C4-alkyl substituents, e. g. methyl, ethyl, prop-1-yl and prop-2-yl, more preferably Ci-C2-alkyl substituents, e. g. methyl, ethyl, especially methyl;
  • R 2 is halogen, cyano, Ci-C4-alkyl, Ci-C4-alkoxy or Ci-C4-haloalkyl, in particular chlorine, fluorine, cyano, methyl, ethyl, methoxy or ethoxy;
  • Table 17 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2,5-difluoro, R 2 is methyl and R 1 for a compound corresponds in each case to one row of Table A
  • Table 18 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2,3,4-trifluoro, R 2 is methyl and R 1 for a compound corresponds in each case to one row of Table A
  • Table 54 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2,4,5-trifluoro, R 2 is chloro and R 1 for a compound corresponds in each case to one row of Table A
  • Table 62 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2,5-difluoro, R 2 is chloro and R 1 for a compound corresponds in each case to one row of Table A
  • Table 70 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2,6-difluoro-4-cyano, R 2 is chloro and R 1 for a compound corresponds in each case to one row of Table A
  • Table 78 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2,6-difluoro,4-methoxy, R 2 is chloro and R 1 for a compound corresponds in each case to one row of Table A
  • Table 86 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2,5-dimethyl,4-bromo, R 2 is chloro and R 1 for a compound corresponds in each case to one row of Table A
  • Table 102 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2-fluoro, R 2 is methoxy and R 1 for a compound corresponds in each case to one row of Table A
  • Table 110 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2,4-dimethyl, R 2 is methoxy and R 1 for a compound corresponds in each case to one row of Table A
  • Table 118 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2-chloro,4-methoxy, R 2 is methoxy and R 1 for a compound corresponds in each case to one row of Table A
  • Table 126 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2-methyl,4-cyano, R 2 is methoxy and R 1 for a compound corresponds in each case to one row of Table A
  • Table 134 Compounds of the formulae I .A, LB, I.C, I.D, I.E, I.F, I.G, I.H, I.J, I.K, I.L, I.M, I.N, I.N, 1.0, I.Q, I. R, I.S, IT, I. U, I.V, I.W and I.X, in which L n is 2-fluoro,5-methyl, R 2 is methoxy and R 1 for a compound corresponds in each case to one row of Table A
  • Table 142 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2-fluoro,4-methoxycarbonyl, R 2 is cyano and R 1 for a compound corresponds in each case to one row of Table A
  • Table 150 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2-chloro-4-fluoro, R 2 is cyano and R 1 for a compound corresponds in each case to one row of Table A
  • Table 158 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2,6-dimethyl, R 2 is cyano and R 1 for a compound corresponds in each case to one row of Table A
  • Table 174 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which L n is 2-methyl,4-methoxy, R 2 is cyano and R 1 for a compound corresponds in each case to one row of Table A
  • 2-substituted pyrimidines of the formula I in particular the compounds of the formulae I .A, I.J, I. K and I. P effectively inhibit growth and/or progeny of tumor cells as can be shown by standard tests on tumor cell lines such as HeLa, MCF-7 and COLO 205.
  • 2-substituted pyrimidines I show in general IC50 values ⁇ 10 "6 mol/l (i.e. ⁇ 1 ⁇ M), preferably IC50 values ⁇ 5x10 "7 mol/l (i.e. ⁇ 500 nM) for cell cycle inhibition in HeLa cells as determined by the test procedure outlined below.
  • 2-substituted pyrimidines are useful as agents for treating, inhibiting or controlling the growth and/or progeny of cancerous tumor cells and associated diseases in a subject in need thereof.
  • these compounds are useful in therapy of cancer in warm blooded vertebrates, i.e. mammals and birds, in particular human beings but also in other mammals of economic and/or social importance e.g. carnivores such as cats and dogs, swine (pigs, hogs and wild boars), ruminats (e.g. cattle, oxen, sheep, deer, goats, bison) and horses, or bird in particular poultry such as turkeys, chickens, ducks, geese, guinea fowl and the like.
  • carnivores such as cats and dogs
  • swine pigs, hogs and wild boars
  • ruminats e.g. cattle, oxen, sheep, deer, goats, bison
  • horses or bird in particular poultry such as turkeys, chickens, ducks, geese, guinea fowl and the like.
  • 2-substituted pyrimidines I are useful in therapy of cancer or cancerous disease including cancer of breast, lung, colon, prostate, melanoma, epidermal, kidney bladder, mouth, larynx, esophagus, stomach, ovary, pancreas, liver, skin and brain.
  • the effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and severity of the condition being treated. However, in general satisfactory results are obtained when the compounds of the invention are administered in amounts ranging from about 0.10 to about 100 mg/kg of body weight per day. A preferred regimen for optimum results would be from about 1 mg to about 20 mg/kg of body weight per day and such dosage units are employed that a total of from about 70 mg to about 1400 mg of the active compound for a subject of about 70 kg of body weight are administered in a 24 hour period.
  • the dosage regimen for treating mammals may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
  • these active compounds may be administered in any convenient manner such as by the oral, intravenous, intramuscular or subcutaneous routes.
  • the active compounds may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatine capsules, or they may be compressed into tablets or they may be incorporated directly with the food of the diet.
  • these active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like.
  • Such compositions and preparations should contain at least 0.1 % of active compound.
  • the percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit.
  • the amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained.
  • Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between 10 and 1000 mg of active compound.
  • the tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatine; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen or cherry flavoring.
  • a binder such as gum tragacanth, acacia, corn starch or gelatine
  • excipients such as dicalcium phosphate
  • a disintegrating agent such as corn starch, potato starch, alginic acid and the like
  • a lubricant such as magnesium stearate
  • a sweetening agent such as sucrose, lactose, or saccharin may be added or a flavoring agent such
  • tablets, pills or capsules may be coated with shellac, sugar or both.
  • a syrup or elixir may contain the active compound, sucrose, as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor.
  • any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts used.
  • these active compounds may be incorporated into sustained-release preparations and formulations.
  • active compounds may also be administered parenterally or intraperitoneal ⁇ .
  • Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose.
  • Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
  • the pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists.
  • the carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid poly-ethylene glycol), suitable mixtures thereof, and vegetable oils.
  • HeLa B cells are grown in DMEM (Life Technologies Cat No 21969-035) supplemented with 10% Fetal Calf Serum (FCS, Life Technologies Cat No 10270-106) in 180 cm 2 Flasks at 37°C, 92% humidity and 7% CO 2 .
  • FCS Fetal Calf Serum
  • the ratio of cells in Go/Gi-phase to G2/M phase is calculated and compared to the value for the controls (DMSO) only. Results are given in table C as the IC50 value calculated from the concentration curve plotted against the cell cycle ratio and indicate the compound concentration at which 50% of cells are in cell cycle arrest after treatment with the compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

The present invention relates to the use of 2-substituted pyridines of the formulaI and the pharmaceutically acceptable salts of the 2-substituted pyridines of formula I in therapy, in particular in therapy or treatment of cancerous diseases: in which the indices and the substituents are as defined in the claims and the specification.

Description

2-Substituted pyrimidines I in therapy
Description
The present invention relates to 2-substituted pyrimidines of the formula I
Figure imgf000002_0001
in which the indices and the substituents are as defined below:
R1 is C2-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, C3-Ci2-cycloalkyl, C4-Ci o- cycloalkenyl, phenyl or a five- to ten-membered saturated, partially unsaturated or aromatic heterocycle which is attached via carbon and which contains one, two, three or four heteroatoms selected from the group consisting of O, N and S; where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of R1 for their part may be partially or fully halogenated or may carry one, two, three or four radicals Rv, which may be the same or different from each other:
Rv is halogen, cyano, Ci-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, C3-Cβ- cycloalkyl, C4-C6-cycloalkenyl, hydroxyl, Ci-Cβ-alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyloxy, C4-C6-cycloalkenyloxy, -C(=O)-A1, -C(=O)-O-A1, -C(=O)-N(A2)A1, C(A2)(=N-OA1), N(A2)A1, N(A2)-C(=O)-A1,
N(A3)-C(=O)-N(A2)A1, S(=O)m-A1, S(=O)m-O-A1 or S(=O)m-N(A2)A1, it also being possible that two vicinal radicals Rv together are (=0), (=S) or (=N-OA1), or Rv is phenyl, where the phenyl moiety may carry one, two or three radicals which may be the same or different from each other and which are selected from the group consisting of: halogen, Ci-Cβ-alkyl,
C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, d-Ce-haloalkyl, Ci-C6- alkoxy, cyano, nitro, -C(=O)-A, C(=O)-O-A, -C(=O)-N(A')A, C(A')(=N-OA) and N(A)A; where
m is O, 1 or 2;
A1, A2, A3, A and A' independently of one another are hydrogen, C-i-Cβ- alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl, C3-C8- cycloalkenyl or phenyl, where the organic radicals may be partially or fully halogenated or may be substituted by halogen, nitro, cyanato, cyano and/or Ci-C4-alkoxy; or A1 and A2, or A and A', respectively, together with the atoms to which they are attached are a five- or six- membered saturated, partially unsaturated or aromatic heterocycle which comprises one, two, three or four heteroatoms selected from the group consisting of O, N and S;
and where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of Rv for their part may be partially or fully halogenated;
R2 is halogen, cyano, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, Cs-Cβ-cycloalkyl, Ci-C4-alkoxy, C3-C4-alkenyloxy, C3-C4-alkynyloxy, d-Cε-alkylthio, di-(Ci-C6- alkyl)amino or Ci-Cβ-alkylamino, where the aliphatic and/or alicyclic groups of the radical definitions of R2 for their part may be partially or fully halogenated or may carry one, two, three or four radicals Ru, which may be the same or different from each other:
Ru is halogen, cyano, Ci-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, hydroxyl,
C-i-Cβ-alkoxy, Cs-Cβ-cycloalkyl, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, C4-C6- cycloalkenyl, Cs-Cβ-cycloalkyloxy, C4-C6-cycloalkenyloxy, -C(=O)-A4, -C(=O)-O-A4, -C(=O)-N(A5)A4, C(A5X=N-OA4), N(A5)A4, N(A5)-C(=O)-A4, N(A6)-C(=O)-N(A5)A4, S(=O)q-A4, S(=O)q-O-A4 or S(=O)q-N(A5)A4, it also being possible that two vicinal radicals Ru together are (=0) or (=S), where
q is O, 1 or 2;
A4, A5 and A6 independently of one another have the meanings of A1, A2 and A3 as defined above;
and where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of Ru for their part may be partially or fully halogenated or may carry one, two or three radicals Rua, which may be the same or different from each other and which have the meanings of Ru as defined above;
R3 is selected from the group consisting of cyano, C(=Z)ORa, C(=Z)NRzRb, C(=Z)NRz-ORa, C(=Z)NRa-NRzRb, C(=Z)Ra, ON(=CRaRb), O-C(=Z)Ra, NRa(C(=Z)Rb), NRa(C(=Z)ORb), NRa(C(=Z)-NRzRb), NRa(N=CRcRb), NRa-NRzRb, NRz-ORa, and the radicals of the formulae R3a and R3b
Figure imgf000003_0001
wherein
Z is O, S, NRa1, NORa1 or N-NRz1Rc1;
Ra, Ra1, Rb, Rc, Rc1 independently of one another are hydrogen, Ci-Cβ- alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Cs-Cβ-cycloalkyl or C4-C6-cycloalkenyl;
Rb1 has the meanings of Rb as defined above, except for hydrogen; and
Rz, Rz1 independently of one another have the meanings of Ra as defined above and may additionally be -CO-Ra2, where Ra2 has the meanings of Ra as defined above;
where the aliphatic and/or alicyclic groups of the radical definitions of Ra, Ra1, Rb, Rb1, Rc, Rc1, Rz and Rz1 for their part may be partially or fully halogenated or may carry one, two, three or four groups R1, which may be the same or different from each other:
R1 is halogen, cyano, Ci-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, d-Cβ-alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyl, Cs-Cβ-cycloalkenyl,
C3-C6-cycloalkoxy or Cs-Cβ-cycloalkenyloxy,
and where two of the radicals Ra, Ra1, Rb, Rb1, Rc, Rc1, Rz or Rz1 together with the atoms, to which they are attached, may form a five-, six- or seven-membered saturated, partially unsaturated or aromatic heterocycle which comprises one, two, three or four heteroatoms selected from the group consisting of O, N and S;
and where # in the formulae R3a and R3b indicates the atom which is bond to the 2-position of the pyrimidine ring
x is O or i ;
Re, Rf, R9, Re# independently of one another are hydrogen, d-Cε-alkyl, C2-Cs-alkenyl, C2-Cs-alkynyl, Cs-Cβ-cycloalkyl, C4-C6-cycloalkenyl,
Rf, Ra together with the nitrogen atom to which they are attached may have the meaning Re-Z-C(Rh)=N;
Q is oxygen or N-Re#;
Q' is C(H)-Rk, C-Rk , N-N(H)-Re# or N-Re#; 1^- may be a double bond or a single bond;
Rh, Rk have the same meanings as Re and may additionally be halogen or cyano; or
Rh together with the carbon to which it is attached may be a carbonyl group;
where the aliphatic, alicyclic or aromatic groups of the radical definitions of Re, Re#, Rf, R9, Rh or Rk for their part may be partially or fully halogenated or may carry one to four groups Rw, which may be the same or different from each other:
Rw is halogen, cyano, Ci-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, d-Cβ-alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyl, C3-C6-cycloalkenyl, Cs-Cβ-cycloalkoxy, Cs-Cβ-cycloalkenyloxy, and where two of the radicals Rf, Rs, Re or Re# together with the atoms to which they are attached may form a five- or six-membered saturated, partially unsaturated or aromatic heterocycle which contains one to four heteroatoms from the group consisting of O, N and S.
n is 1 , 2, 3, 4 or 5;
L is halogen, cyano, cyanato (OCN), Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, Ci-Cβ-alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyl, C4-C6- cycloalkenyl, Cs-Cβ-cycloalkyloxy, C4-C6-cycloalkenyloxy, nitro, -C(=O)-A10, -C(=O)-O-A10, -C(=O)-N(A11)A10, -C(=S)-N(A11)A10, -C(=NA11)-SA10,
-C(A11)(=N-OA10), -N(A11)A10, -N(A11)-C(=O)-A10, -N(A12)-C(=O)-N(A11)A10, -S(=O)p-A10, -S(=O)p-O-A10 or -S(=O)p-N(A11)A10, where
p is 0, 1 or 2;
A10, A11, A12 independently of one another have the meanings of A1, A2 and A3 as defined above;
where L may be identical or different from each other and where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of L for their part may be partially or fully halogenated or may carry one, two, three or four radicals RL, which may be the same or different from each other:
RL is halogen, cyano, Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, hydroxyl, Ci-Cβ-alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyl, C4-C6- cycloalkenyl, Cs-Cβ-cycloalkyloxy, C4-C6-cycloalkenyloxy, -C(=O)-A13, -C(=O)-O-A13, -C(=O)-N(A14)A13, C(A14X=N-OA13), N(A14)A13, N(A14)-C(=O)-A13, N(A15)-C(=O)-N(A14)A13, S(=O)S-A13, S(=O)S-O-A13 or S(=O)s-N(A14)A13; it also being possible that two vicinal radicals RL together are (=0) or (=S), where
s is 0, 1 or 2; and
A13, A14 and A15 independently of one another have the meanings of A1, A2 and A3 as defined above;
and where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of RL for their part may be partially or fully halogenated or may carry one, two, three or four groups RLA, which may be the same or different from each other and which have the meanings of RL as defined above;
and the pharmaceutically acceptable salts of the 2-substituted pyrimidines of formula I for use in therapy, i.e. in the therapy of a disease in an animal being in particular a humen being, in particular in therapy or treatment of cancer or a cancerous diseases, respectively.
The invention also relates to pharmaceutical compositions comprising a 2-substituted pyrimidine of the formula I as defined herein or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier. Moreover the invention relates to the use of a 2-substituted pyrimidine of the formula I as defined herein and of their pharmaceutically acceptable salts in the manufacture of a medicament in particular a medicament for therapy or treatment of cancer or a cancerous disease, respectively. The invention also provides a method for cancer treatment, which comprises administering to the subject in need thereof an effective amount of a 2-substituted pyrimidine of the formula I as defined herein or of their pharmaceutically acceptable salts.
Despite dramatic advances in research and novel treatment options, cancer is still one of the leading causes of death. Amongst the different types of cancer such as lung, breast, prostate and colon cancer as well as colon lymphomas, are most frequently diagnosed and ovarian cancer is the 2nd most common reproductive cancer after breast cancer in women. A large number of cytotoxic compounds are known to effectively inhibit the growth of tumor cells, including taxoides like paclitaxel (Taxole), docetaxel (Taxotere), the vinka alkaloids vinorelbine, vinblastine, vindesine and vincristine. However, these compounds are natural products having a complex structure and thus are difficult to produce. EP-A 715 851 discribes pharmacologically active 5-phenylpyrimidines which may carry, among other substituents, a piperazine or morpholine radical or an amino group which is mono- or disubstituted by alkyl and/or aryl in the 2-position, and which, among other radicals may carry an alkyl radical or certain substituted alkyl radicals in the 4-position
WO 2005/030216 describes pharmacologically active 5-phenylpyrimidines which carry an aryl, heteroaryl or a substituted amino group in the 2-position and a secondary amino group or cycloalkyl group in the 4-position. The compounds are mentioned to be usefull as anticancer agents.
Furthermore, WO 2006/079556 teaches 5-phenylpyrimidines which carry a substituted amino or alkoxy radical in the 4-postion and further radicals in the 2- and 6-positions of the pyrimidine ring to be useful in anticancer therapy.
However, there is still a need to adapt such compounds by modification in order to increase their efficiency, to broaden or further specify their range of application and/or to minimize the side effects accociated with their application.
It is, therefore, an object of the present invention to provide compounds which effectively control or inhibit growth and/or progeny of tumor cells and thus are useful in the treatment of cancer. It is highly desirable that these compounds can be synthesized from simple starting compounds according to standard methods of organic chemistry.
We have found that these and further objects are achieved by the 2-substituted pyrimidines I defined at the outset. Furthermore, we have found a method for treating cancer, which comprises administering to the subject in need thereof an effective amount of a 2-substituted pyrimidine I as defined herein or of their pharmaceutically acceptable salts.
2-Substituted pyrimidines of the formula I have been described in WO 2004/087678. The compounds disclosed therein are active against various phytopathogenic fungi. However, these documents do not describe or suggest that these compounds may be effective in the treatment of diseases or even in the treatment of cancer. 2-Substituted pyrimidines I can be prepared by the methods disclosed in WO 2004/087678 as well as by analogy to the methods described in WO 2004/103978 and in the literature cited therein as well as by standard methods of organic chemistry.
It is likewise possible to use physiologically tolerated salts of the 2-substituted pyrimidines I, especially acid addition salts with physiologically tolerated acids. Examples of suitable physiologically tolerated organic and inorganic acids are hydrochloric acid, hydrobromic acid, phosphoric acid, nitric acid, sulfuric acid, organic sulfonic acids having from 1 to 12 carbon atoms, e.g. Ci-C4-alkylsulfonic acids such as methanesulfonic acid, cycloaliphatic sulfonic acids such as S-(+)-10-camphorsulfonic acids and aromatic sulfonic acids such as benzenesulfonic acid and toluenesulfonic acid, di- and tricarboxylic acids and hydroxycarboxylic acids having from 2 to 10 carbon atoms such as oxalic acid, malonic acid, maleic acid, fumaric acid, mucic acid, lactic acid, tartaric acid, citric acid, glycolic acid and adipic acid, as well as cis- and trans- cinnamic acid, furoic acid and benzoic acid. Other utilizable acids are described in Fortschritte der Arzneimittelforschung [Advances in Drug Research], Volume 10, pages 224 ff., Birkhauser Verlag, Basel and Stuttgart, 1966. The physiologically tolerated salts of 2-substituted pyrimidines I may be present as the mono-, bis-, tris- and tetrakis-salts, that is, they may contain 1 , 2, 3 or 4 of the aforementioned acid molecules per molecule of formula I. The acid molecules may be present in their acidic form or as an anion. The acid addition salts are prepared in a customary manner by mixing the free base of a 2-substituted pyrimidine I with a corresponding acid, where appropriate in solution in water or an organic solvent as for example a lower alcohol such as methanol, ethanol, n-propanol or isopropanol, an ether such as methyl tert-butyl ether or diisopropyl ether, a ketone such as acetone or methyl ethyl ketone, or an ester such as ethyl acetate. Solvents, wherein the acid addition salt of I is insoluble (anti-solvents), might be added to precipitate the salt. Suitable anti-solvents comprise C1-C4- alkylesters of Ci-C4-aliphatic acids such as ethyl acetate, aliphatic and cycloaliphatic hydrocarbons such as hexane, cyclohexane, heptane, etc., di-Ci-C4-alkylethers such as methyl tert-butyl ether or diisopropyl ether.
In the symbol definitions given in formula I above, collective terms were used which generally represent the following substituents:
- halogen: fluorine, chlorine, bromine or iodine, in particular chlorine or fluorine;
- alkyl and the alkyl moieties of alkoxy, alkylthio, alkylcarbonyl, alkoxycarbonyl, alkylamino, di(alkyl)amino, alkylaminocarbonyl, di(alkyl)amincarbonyl, alkylcarbonylamino, alkylsulfinyl, alkylsulfonyl, alkylaminosulfonyl or di(alkyl)aminosulfonyl: saturated, straight-chain or branched hydrocarbon radicals having 1 to 10, preferably 1 to 8 carbon atoms, more preferably 1 to 6 carbon atoms, especially 1 to 4 carbon atoms, such as methyl, ethyl, propyl, 1-methylethyl, butyl, 1-methylpropyl, 2-methylpropyl, 1 ,1-dimethylethyl, pentyl, 1-methylbutyl, 2-methylbutyl, 3-methylbutyl, 2,2-di-methylpropyl, 1-ethylpropyl, hexyl, 1 ,1-dimethylpropyl,
1 ,2-dimethylpropyl, 1-methylpentyl, 2-methyl pentyl, 3-methylpentyl, 4-methylpentyl, 1 ,1-dimethylbutyl, 1 ,2-dimethylbutyl, 1 ,3-dimethylbutyl, 2,2-dimethylbutyl, 2,3-dimethylbutyl, 3,3-dimethylbutyl, 1-ethylbutyl, 2-ethylbutyl, 1 ,1 ,2-trimethylpropyl, 1 ,2,2-trimethylpropyl, 1-ethyl-1-methylpropyl and 1-ethyl-2-methylpropyl;
- alkenyl and the alkenyl moieties of alkenyloxy: unsaturated, straight-chain or branched hydrocarbon radicals having 2 to 10, preferably 2 to 6, and in particular 2 to 4 carbon atoms, and a double bond in any position, especially C3-C4-alkenyl, for example ethenyl, 1-propenyl, 2-propenyl, 1-methylethenyl, 1-butenyl, 2-butenyl, 3-butenyl, 1-methyl-1-propenyl, 2-methyl-1-propenyl, 1-methyl-2-propenyl, 2-methyl-2-propenyl, 1-pentenyl, 2-pentenyl, 3-pentenyl, 4-pentenyl, 1-methyl-1-butenyl, 2-methyl-1-butenyl, 3-methyl-1-butenyl, 1-methyl-2-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl,
1-methyl-3-butenyl, 2-methyl-3-butenyl, 3-methyl-3-butenyl, 1 ,1-dimethyl-2-propenyl, 1 ,2-dimethyl-1-propenyl, 1 ,2-dimethyl-2-propenyl, 1-ethyl-1-propenyl, 1-ethyl-2-propenyl, 1-hexenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 1-methyl-1-pentenyl, 2-methyl-1-pentenyl, 3-methyl-1-pentenyl, 4-methyl-1-pentenyl, 1-methyl-2-pentenyl, 2-methyl-2-pentenyl, 3-methyl-2-pentenyl, 4-methyl-2-pentenyl, 1-methyl-3-pentenyl, 2-methyl-3-pentenyl, 3-methyl-3-pentenyl, 4-methyl-3-pentenyl, 1-methyl-4-pentenyl, 2-methyl-4-pentenyl, 3-methyl-4-pentenyl, 4-methyl-4-pentenyl, 1 ,1-dimethyl-2-butenyl, 1 ,1-dimethyl-3-butenyl, 1 ,2-dimethyl-1-butenyl, 1 ,2-dimethyl-2-butenyl, 1 ,2-dimethyl-3-butenyl, 1 ,3-dimethyl-1-butenyl, 1 ,3-dimethyl-2-butenyl, 1 ,3-dimethyl-3-butenyl, 2,2-dimethyl-3-butenyl, 2,3-dimethyl-1-butenyl, 2,3-dimethyl-2-butenyl, 2,3-dimethyl-3-butenyl, 3,3-dimethyl-1-butenyl, 3,3-dimethyl-2-butenyl, 1-ethyl-1-butenyl, 1-ethyl-2-butenyl, 1-ethyl-3-butenyl, 2-ethyl-1-butenyl, 2-ethyl-2-butenyl, 2-ethyl-3-butenyl, 1 ,1 ,2-trimethyl-2-propenyl, 1-ethyl-1-methyl-2-propenyl, 1-ethyl-2-methyl-1-propenyl and 1-ethyl-2-methyl-2-propenyl;
- alkadienyl: unsaturated straight-chain or branched hydrocarbon radicals having 4 to 8, in particular 4 to 6 carbon atoms and two double bonds in any position, for example butadiene, 1 ,3-pentadiene, 1 ,4-pentadiene, 1 ,3-hexadiene, 1 ,4-hexadiene and 1 ,5-hexadiene;
- alkynyl: straight-chain or branched hydrocarbon radicals having 2 to 10, preferably 2 to 6, in particular 2 to 4 carbon atoms, and a triple bond in any position, especially C3-C4-alkynyl, for example ethynyl, 1-propynyl, 2-propynyl, 1-butynyl, 2-butynyl, 3-butynyl, 1-methyl-2-propynyl, 1-pentynyl, 2-pentynyl, 3-pentynyl, 4-pentynyl, 1-methyl-2-butynyl, 1-methyl-3-butynyl, 2-methyl-3-butynyl, 3-methyl-1-butynyl, 1 ,1-dimethyl-2-propynyl, 1-ethyl-2-propynyl, 1-hexynyl, 2-hexynyl, 3-hexynyl, 4-hexynyl, 5-hexynyl, 1-methyl-2-pentynyl, 1-methyl-3-pentynyl, 1-methyl-4-pentynyl, 2-methyl-3-pentynyl, 2-methyl-4-pentynyl, 3-methyl-1-pentynyl, 3-methyl-4-pentynyl, 4-methyl-1-pentynyl, 4-methyl-2-pentynyl, 1 ,1-dimethyl-2-butynyl,
1 ,1-dimethyl-3-butynyl, 1 ,2-dimethyl-3-butynyl, 2,2-dimethyl-3-butynyl, 3,3-dimethyl-1-butynyl, 1-ethyl-2-butynyl, 1-ethyl-3-butynyl, 2-ethyl-3-butynyl and 1 -ethyl-1 -methyl-2-propynyl;
- cycloalkyl: mono- or bicyclic hydrocarbon radicals having 3 to 10 carbon atoms; monocyclic groups having 3 to 8, especially 3 to 6 ring members, for example C3-C8-cycloalkyl such as cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl;
- haloalkyl and the haloalkyl moieties of haloalkoxy: straight-chain or branched alkyl groups having 1 to 10 carbon atoms, preferably 1 to 6 carbon atoms, especially 1 to 4 carbon atoms (as mentioned above), where the hydrogen atoms in these groups may be partially or fully replaced by halogen atoms as mentioned above, for example Ci-C4-haloalkyl, such as chloromethyl, bromomethyl, dichloromethyl, trichloromethyl, fluoromethyl, difluoromethyl, trifluoromethyl, chlorofluoromethyl, dichlorofluoromethyl, chlorodifluoromethyl, 1-chloroethyl, 1-bromoethyl, 1-fluoroethyl, 2-fluoroethyl,
2,2-difluoroethyl, 2,2,2-trifluoroethyl, 2-chloro-2-fluoroethyl, 2-chloro-2,2-difluoroethyl, 2,2-dichloro-2-fluoroethyl, 2,2,2-trichloroethyl, pentafluoroethyl, 1 ,1 ,1-trichloroprop-1-yl, 1 ,1 ,1-trifluoroprop-1-yl, 1 ,1 ,1 -trichloroprop-2-yl and 1 ,1 ,1-trifluoroprop-2-yl; similar considerations apply to other halogenated groups such as haloalkenyl, haloalkynyl and halocycloalkyl where the hydrogen atoms of the alkenyl, alkynyl and cycloalkyl groups may be partially or fully replaced by halogen atoms as mentioned above;
- oxy-alkyleneoxy: divalent straight-chain hydrocarbon radicals having 2 to 3 carbon atoms, e.g. OCH2CH2O or OCH2CH2CH2O;
- 5-, 6-, 7-, 8-, 9- or 10-membered heterocycle: homo- or bicyclic hydrocarbon radicals containing one to four heteroatoms selected from the group consisting of a nitrogen atom, an oxygen atom and a sulfur atom; unsaturated (heterocyclyl) includes partially unsaturated, e.g. mono-unsaturated, and aromatic (heteroaryl); said heterocycles in particular include:
- 5-membered heteroaryl, containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom: 5-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom as ring members, for example 2-furyl, 3-furyl, 2-thienyl, 3-thienyl, thiophenyl, 2-pyrrolyl, 3-pyrrolyl, 3-isoxazolyl, 4-isoxazolyl, 5-isoxazolyl, 3-isothiazolyl, 4-isothiazolyl, 5-isothiazolyl, 1-pyrazolyl, 3-pyrazolyl, 4-pyrazolyl, 5-pyrazolyl, 2-oxazolyl, 4-oxazolyl, 5-oxazolyl, 2-thiazolyl, 4-thiazolyl, 5-thiazolyl, 2-imidazolyl, 4-imidazolyl, 1 ,2,4-oxadiazol-3-yl, 1 ,2,4-oxadiazol-5-yl, 1 ,2,4-thiadiazol-3-yl, 1 ,2,4-thiadiazol-5-yl, 1 ,2,3-triazol-1 -yl, 1 ,2,4-triazol-1 -yl, 1 ,2,4-triazol-3-yl, tetrazolyl, 1 ,3,4-oxadiazol-2-yl, 1 ,3,4-thiadiazol-2-yl and 1 ,3,4-triazol-2-yl;
- 6-membered heteroaryl, containing one to four nitrogen atoms: 6-membered heteroaryl groups which, in addition to carbon atoms, may contain one to three or one to four nitrogen atoms as ring members, for example 2-pyridinyl, 3-pyridinyl, 4-pyridinyl, 3-pyτidazinyl, 4-pyridazinyl, 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl, 2-pyrazinyl, 1 ,2,3-triazinyl, 1 ,3,5-triazin-2-yl and 1 ,2,4-triazin-3-yl.
- 9- or 10-membered heteroaryl, containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom: 9- or 10-membered heteroaryl groups which, in addition to carbon atoms, may contain one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom as ring members, in particular benzo-fused 5- or 6-membered heteroaryl which contains one to three nitrogen atoms or one nitrogen atom and one oxygen or sulfur atom (i. e. 5- or 6-membered heteroaryl groups which, in addition to carbon atoms, contain one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom as ring members and in which two adjacent carbon ring members or one nitrogen and one adjacent carbon ring member may be bridged by a buta-1 ,3-dien-1 ,4-diyl group), for example benzothiazol-2-yl, 1 H-indol-1-yl, 1 H-indol-2-yl, 1 H-indol-3-yl, 1 H-indazol-1-yl, 1 H-indazol-2-yl, benzofuran- 2-yl and benzofuran-3-yl; quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, isoquinolin-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, phthalazinyl, quinoxalinyl, quinazolin-2-yl, quinazolin-4-yl, cinnolin-3-yl and cinnolin-4-yl.
- 5-, 6- and 7-membered heterocyclyl, containing one to four nitrogen atoms or one to three nitrogen atoms and one sulfur or oxygen atom: 3-pyrazolidinyl, 4-pyrazolidinyl,
5-pyrazolidinyl, 2-pyrrolidin-2-yl, 2-pyrrolidin-3-yl, 3-pyrrolidin-2-yl, 3-pyrrolidin-3-yl, pyrrolidon-1-yl, pyrrolidin-2-thion-1-yl, 1-piperidinyl, 2-piperidinyl, 3-piperidinyl, 4-piperidinyl, pyridin(1 ,2-dihydro)-2-on-1-yl, 2-piperazinyl, 1-pyrimidinyl, 2-pyrimidinyl, morpholin-4-yl, thiomorpholin-4-yl, dihydrothiazol-2-yl, piperidin-2-on-1-yl, piperidin-2-thion-1-yl, dihydropyridinyl, hexahydroazepin-1-yl and hexahydroazepin-2-thion-1 -yl.
The scope of the present invention includes the (R) and (S) isomers of the formula I having chiral centers. Thus, it is to be understood that any mixture of the (R) and (S) isomer compounds in any ratio including the racemates is also within the scope of the present invention.
With regard to their activity to inhibit growth and progeny of tumor cells preference is given to 2-substituted pyrimidines I, wherein R1 is different from C3-Cio-cycloalkyl or C3-Cio-cycloalkenyl. In particular R1 is C2-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, where the aliphatic groups of the radical definitions of R1 for their part may be unsubstituted, partially or fully halogenated or may carry one, two, three or four radicals Rv which may be the same or different from each other:
Rv is as defined above and preferably selected from halogen, cyano, Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, Cs-Cβ-cycloalkyl, C4-C6-cycloalkenyl, hydroxyl (= OH), d-Cβ-alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyloxy, C4-C6-cycloalkenyloxy, -C(=O)-A1, -C(=O)-O-A1, -C(=O)-N(A2)A1, C(A2)(=N-OA1), N(A2)A1, N(A2)-C(=O)-A1, N(A3)-C(=O)-N(A2)A1, S(=O)m-A1, S(=O)m-O-A1 and S(=O)m-N(A2)A1, it also being possible that two vicinal radicals Rv together are (=0), (=S) or (=N-OA1).
Particular preference is given to 2-substituted pyrimidines I wherein R1 is C2-C8-alkyl, C2-C8-haloalkyl, C2-C8-alkenyl, C2-C8-haloalkenyl, C2-Cs-alkynyl or C2-C8-haloalkynyl, more particularly d-Cs-alkyl, Ci-Cs-haloalkyl, d-Cs-alkenyl or C2-C8-haloalkenyl, where the aliphatic groups may carry one or two, especially one radical(s) Rv which may be the same or different from each other and which are preferably selected from the group consisting of Ci-Cβ-alkyl, d-drhaloalkyl, hydroxyl, Ci-Cβ-alkoxy, C3-C6- cycloalkyl, d.-drhalocycloalkyl, and phenyl, where the phenyl moiety may carry one, two or three, especially one radical(s) which may be the same or different from each other and which are selected from the group consisting of: halogen, d-Cβ-alkyl, d-Cβ- haloalkyl, d-Cβ-alkoxy, cyano and nitro. In particular, the radicals Rv, if present, are selected from the group consisting of hydroxyl and d-Cβ-alkoxy, preferably hydroxyl and d-d-alkoxy such as methoxy, ethoxy, propoxy and butoxy.
A preferred embodiment of the invention relates to 2-substituted pyrimidines I, wherein R1 is linear C2-C8-alkyl or C2-C8-haloalkyl, i.e. n-C2-C8-alkyl or n-C2-C8-haloalkyl, preferably n-C2-C6-alkyl and more preferably n-C2-d-alkyl, i. e. where the chain of carbon atoms of the alkyl radical is not branched but linear, e. g. ethyl, n-propyl and n-butyl, particularly methyl and ethyl.
A more preferred embodiment of the invention relates to 2-substituted pyrimidines I wherein R1 is d-Cs-alkyl or d-Cs-haloalkyl, preferably d-Cβ-alkyl, which in each case is branched but preferably not branched in the α-position (e. g. branched in the β- or γ-position), and which is unsubstituted or may carry one or two, especially one radical Rv selected from the group consisting of hydroxyl and d-d-alkoxy such as methoxy or ethoxy, e. g. (2-methyl)-but-1-yl, (3-methyl)-but-1-yl, (2,2-dimethyl)-but-1-yl, (2,3-dimethyl)-but-1 -yl, (3,3-dimethyl)-but-1 -yl, 2-hydroxy-(3-methyl)-but-1 -yl, 3-hydroxy-(3-methyl)-but-1 -yl, 4-hydroxy-(3-methyl)-but-1 -yl, 2-hydroxy-(2-methyl)-but-1 -yl, 3-hydroxy-(2-methyl)-but-1 -yl, 4-hydroxy-(2-methyl)-but-1-yl and (2-methyl)-prop-1-yl, more preferably (2-methyl)-but-1 -yl, 2-hydroxy-(3-methyl)-but-1 -yl and (2-methyl)-prop-1 -yl.
Another preferred embodiment of the invention relates to 2-substituted pyrimidines I wherein R1 is d-Cs-alkenyl or d-Cs-haloalkenyl, preferably d-Cs-alkenyl, e. g. but-1-en-4-yl (= but-3-en-1-yl), but-2-en-1-yl, 2-methyl-but-1-enyl, 3-methyl-but-1-enyl, 2-methyl-but-2-en-1-yl and 3-methyl-but-2-en-1-yl, more preferably but-1-en-4-yl and 3-methyl-but-1 -enyl. If R1 is branched or carries a halogen atom or a subsitutend Rv, R1 may have a center of chirality. If R1 carries a halogen atom creating a center of chirality, the (S)-isomers are preferred for these groups. In the case of halogen-free alkyl or alkenyl groups having a center of chirality in R1, preference is given to the (R)-configured isomers.
Another preferred embodiment of the invention relates to 2-substituted pyrimidines I, wherein R1 is a saturated, partially unsaturated or aromatic, preferably saturated five- or six-membered carbocycle, i.e. C3-Ci2-cycloalkyl, C3-Cio-cycloalkenyl or phenyl, or a C-bound heterocycle which may carry an oxygen atom (-O-), an imino nitrogen (=N-) or an amino -(-N(RX)- group as ring member, where Rx is hydrogen or d-Cε-alkyl, and/or where the ring formed may carry one or more, e. g. 1 , 2, 3 or 4, preferably 1 substituent(s) from the group consisting of halogen, d-Cε-alkyl, d-Cε-haloalkyl and oxy-Ci-C3-alkyleneoxy, in particular halogen, d-Cε-alkyl and C-i-Cε-haloalkyl. Amongst these, particular preference is given to compounds I, wherein R1 is a saturated or unsaturated, preferably saturated five- or six-membered C-bound heterocycle which carries an oxygen atom or a nitrogen atom or an amino -(-N(RX)- group as ring member, examples including tetrahydrofuranyl, tetrahydropyranyl, pyrrolidinyl and piperidinyl, e. g. pyrrolidin-2-yl and piperidin-2-yl, and which may carry one or two Ci-Cβ-alkyl, preferably Ci-C4-alkyl substituents, e. g. methyl, ethyl, prop-1-yl and prop- 2-yl, more preferably Ci-C2-alkyl substituents, e. g. methyl, ethyl, especially methyl. Very particular preference is given to the aforementioned 2-substituted pyrimidines I wherein the heterocycle which includes R1 is unsubstituted or is methylated, e. g. 5-methylpyrrolidin-2-yl, 6-methylpiperidin-2-yl and 4-methylpiperidin-2-yl.
With regard to their activity to inhibit growth and progeny of tumor cells preference is furthermore given to 2-substituted pyrimidines I in which R2 is halogen, cyano, C1-C4- alkyl, Ci-C4-haloalkyl or Ci-C4-alkoxy, in particular fluorine, chlorine, bromine, methyl, cyano, methoxy or ethoxy, more preferably fluorine, chlorine, cyano, methyl or methoxy. Particularly preferred are compounds of the formula I, wherein R2 is chlorine, cyano or methyl.
Preference is furthermore given to 2-substituted pyrimidines I in which R3 is cyano, C(=O)NRzRb, C(=NRa1)NRzRb, C(=NORa1)NRzRb, C(=N-NRz1Rc1)NRzRb, C(=S)NRzRb, C(=O)Ra, C(=NRa1)Ra, C(=NORa1)Ra, C(=N-NRz1Rc1)Ra, C(=O)ORa, C(=NRa1)ORa, C(=NORa1)ORa, C(=O)NRz-ORa, C(=NRa1)NRz-ORa, C(=NORa1)NRz-ORa, or C(=O)NRa-NRzRb.
Preference is likewise given to 2-substituted pyrimidines I in which R3 is O-C(=O)Ra or ON(=CRaRb). Preference is likewise given to 2-substituted pyrimidines I in which R3 is NRa(C(=0)Rb), NRa(C(=S)Rb), NRa(C(=NRa1)Rb), NRa(C(=N0Ra1)Rb), NRa(C(=0)0Rb), NRa(C(=0)-NRzRb), NRa(C(=NRa1)-NRzRb), NRa(N=CRcRb), NRa-NRzRb or NRz-ORa.
Particular preference is given to 2-substituted pyrimidines I, where R3 is cyano,
C(=S)NRzRb, C(=O)NRzRb, C(=NORa1)NRzRb, C(=NRa1)NRzRb, C(=O)Ra, C(=NORa1)Ra, C(=NRa1)Ra, C(=O)ORa, C(=NORa1)ORa, C(=NRa1)ORa, C(=O)NRz-ORa, C(=NORa1)NRz-ORa, C(=NRa1)NRz-ORa, C(=N-NRz1Rc1)Ra, ON(=CRaRb), NRa(C(=O)Rb), NRa(C(=O)ORb), NRa(N=CRcRb) or NRz-ORa.
Among the aforementioned compounds I, those are preferred where Ra, Ra1, Rb, Rc and Rc1 independently of one another are hydrogen, d-Cε-alkyl, d-Cε-haloalkyl, C2-C6- alkenyl, C2-C6-haloalkenyl, C2-C6-alkynyl, C2-C6-haloalkynyl, C3-C6-cycloalkyl, C3-C6- halocycloalkyl, C4-C6-cycloalkenyl or C4-C6-halocycloalkenyl, more preferably hydrogen, Ci-C4-alkyl, Ci-C4-haloalkyl, C2-C4-alkenyl, C2-C4-alkynyl or C3-C6- cycloalkyl, especially hydrogen or Ci-C4-alkyl. Likewise, those compounds I are preferred where Rb1 has the preferred meanings of Rb as defined above, except for hydrogen. Likewise, those compounds I are preferred where Rz and Rz1 independently of one another have the preferred meanings of Ra as defined above or are -CO-Ra2, where Ra2 has the preferred meanings of Ra as defined above.
A particular preferred embodiment of the invention relates to 2-substituted pyrimidines I, where R3 is selected from the croup consisting of cyano, C(=O)NRzRb, C(=NORa1)NRzRb, C(=NORa1)Ra, NRa(C(=O)ORb), ON(=CRaRb), NRa(C(=O)Rb), NRa(C(=S)Rb) and C(=S)NRzRb. Among these compounds I, those are more preferred where Ra and Ra1 independently of one another are hydrogen or Ci-C4-alkyl, especially Ci-C2-alkyl, e. g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl. More preferably Ra is hydrogen, methyl, ethyl, n-propyl or iso-propyl. Likewise, more preferably Ra1 is methyl. Furthermore, those compounds I are more particularly preferred where Rb is hydrogen or Ci-C4-alkyl, especially Ci-C2-alkyl, e. g. methyl or ethyl, in particular methyl. More preferably Rb is hydrogen or methyl. Likewise, those compounds I are more particularly preferred where Rz is hydrogen, Ci-C4-alkyl, e. g. methyl, ethyl, n-propyl, iso-propyl, n-butyl, iso-butyl or tert-butyl, in particular methyl, or -CO-Ra2, where Ra2 is Ci-C4-alkyl, e. g. methyl or ethyl, in particular methyl. More preferably Rz is hydrogen, methyl or -CO-Ra2, and Ra2 is methyl. Very particular preference is given to 2-substituted pyrimidines I, where R3 is selected from the group consisting of cyano, C(=O)NHCH3, C(=NOCH3)NH2, C(=NOH)NH2, C(=NOCH3)CH3, C(=NOH)CH3, NH(C(=O)OCH3), N(C(=O)CH3)-OCH3, ON(=C(CH3)2), NH(C(=O)CH3), C(=O)NH2, C(=S)NH2, C(=O)-O(CH3), C(=O)-O(CH2CH3), C(=O)-O(CH2CH2CH3) and C(=O)-OCH(CH3)2, with most preference given to R3 being selected from the group consisting of cyano, C(=NOCH3)NH2, C(=NOH)NH2,C(=O)NH2 and C(=S)NH2. In another embodiment of the invention R3 is selected from C(=Z)ORa, C(=Z)NRz-ORa or C(=Z)Ra, preferably C(=O)ORa, C(=NRa1)ORa, C(=NORa1)ORa, C(=O)NRz-ORa, C(=NRa1)NRz-ORa, C(=NORa1)NRz-ORa, C(=O)Ra, C(=NRa1)Ra and C(=NORa1)Ra. Among these compounds I, those are more particularly preferred where Ra1 is hydrogen or Ci-C4-alkyl, especially Ci-C2-alkyl, in particular methyl. Likewise, those compounds I are more particularly preferred where Ra and/or Rb, especially both Ra and Rb are hydrogen. Likewise, those compounds I are more particularly preferred where Rz is hydrogen or -CO-Ra2, a particular preferred radical R3 being C(=NH)N(CO-Ra2)Rb, where Ra2 and Rb independently from one another preferably are hydrogen or Ci-C4-alkyl such as methyl and ethyl.
Very particular preference is given to 2-substituted pyrimidines I, where R3 is selected from the group consisting of cyano, C(=NOCH3)NH2, C(=NOH)NH2, C(=NH)NH2, C(=O)NH2, C(=S)NH2, C(=NH)NH-OH, C(=O)NH-OH and C(=NH)NH-C(=O)CH3, especially cyano, C(=NOCH3)NH2, C(=NOH)NH2, C(=O)NH2 and C(=S)NH2.
In a further preferred embodiment of the invention the radical R3 is selected from NRa(C(=O)Rb) and NRa(C(=S)Rb), wherein Ra and Rb together form a C2-C5-alkylene or C3-C5-alkenylene moiety. In this embodiment particular preference is given to compounds, wherein R3 is pyrrolidin-2-on-1-yl, piperidin-2-on-1-yl, azepin-2-on1-yl, pyrrolidin-2-thion-1-yl, piperidin-2-thion-1-yl or azepin-2-thion-1-yl.
In a further preferred embodiment of the invention the radical R3 is a radical of the formulae R3a or R3b as defined above. Preferably, the radical R3b corresponds one of the following formulae:
Figure imgf000015_0001
wherein Re#, Rs and Rh are as defined above. In these formulae Re#, R9 and Rh are preferably independently of one another hydrogen, d-Cε-alkyl, C2-C6-alkenyl,
C2-C6-alkynyl or Cs-Cβ-cycloalkyl, in particular are hydrogen, methyl or ethyl. Amongst these preference is given to radicals R3b of the formulae:
Figure imgf000015_0002
wherein Re#, Rs and Rh are as defined above. Examples for these radicals include radicals of the following formulae:
Figure imgf000016_0001
Likewise, preference is given to 5-phenyl pyrimidines I, wherein the radical R3 in the 2-position is of the formula R3a:
Figure imgf000016_0002
wherein Q, Re, Rf and Rs are as deffned above. Preferably Q is oxygen. Preferably Re, Rf and Rs are independently of one another hydrogen, d-Cε-alkyl, C2-C6-alkenyl, C2-C6-alkynyl or Cs-Cβ-cycloalkyl, in particular hydrogen, methyl or ethyl or Rf and Rs together with the nitrogen are a radical Re-Q-C(Rh)=N, wherein Q, Re and Rh are as defined above. In particular Q is oxygen and Re and Rh are H or d-Cε-alkyl. Examples of this type of radical R3a include:
Figure imgf000016_0003
Preference is furthermore given to 2-substituted pyrimidines I, where the substituents L, which are attached to the phenyl ring, hereinafter also referred to as substituents L1 to L5, are independently of each other selected from the group consisting of:
L halogen, in particular fluorine, chlorine, bromine, preferably fluorine, chlorine; cyano; Ci-Cs-alkyl, in particular d-Cε-alkyl, especially Ci-C4-alkyl, such as methyl, ethyl, propyl and butyl, preferably methyl; C2-Cio-alkenyl, in particular
C2-C6-alkenyl, especially C2-C4-alkenyl, such as ethenyl, propenyl and butenyl; C2-Cio-alkynyl, in particular C2-C6-alkynyl, especially C2-C4-alkynyl, such as ethynyl, propynyl and butynyl; d-Cβ-alkoxy, in particular Ci-C4-alkoxy, preferably methoxy and ethoxy; C2-Cio-alkenyloxy, in particular C2-C6-alkenyloxy, such as ethenyloxy; C2-Cio-alkynyloxy, in particular C2-C6-alkynyloxy, such as ethynyloxy; nitro; -C(=O)-O-A10, in particular Ci-C4-alkoxycarbonyl, especially Ci-C2-alkoxycarbonyl, such as methoxycarbonyl; -C(=O)-N(A11)A10, in particular CO-NH2, Ci-C4-alkylaminocarbonyl, such as CO-NHCH3 and CO-NHC2H5, and di-(Ci-C4-alkyl)-aminocarbonyl, such as CO-N(CHs)2; -C(=S)-N(A11)A10, in particular CS-NH2, C-i-d-alkylaminothiocarbonyl, such as CS-NHCH3, and di-d-Gralkylaminothiocarbonyl, such as CS-N(CHs)2; C(A11X=N-OA10), such as CH(=NOH) and CH(=NOCH3); N(A11)A10, in particular Ci-C4-alkylamino and di-Ci-C4-alkylamino; N(A11)-C(=O)-A10, in particular d-d-alkylcarbonylamino, such as NH-C(=O)CH3, and N-(Ci-C4-alkylcarbonyl)-N-(Ci-C4-alkyl)-amino, such as N(CH3)-C(=O)CH3, and/or S(=O)P-A10, in particular -SH, Ci-C4-alkylthio, such as SCH3, or Ci-C4-alkylsulfonyl, such as SO2CH3; where
A10, A11 independently of one another are hydrogen, Ci-Cβ-alkyl, C2-Cβ- alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl or phenyl, where the organic radicals may be partially or fully halogenated or may be substituted by halogen, cyano and/or Ci-C4-alkoxy; or A10 and A11 together with the atoms to which they are attached are a five- or six-membered saturated heterocycle which comprises one or two heteroatoms from the group consisting of O, N and S;
where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of L for their part may be partially or fully halogenated, e. g. where L may be C-i-Cβ- haloalkyl, especially Ci-C2-fluoroalkyl, such as trifluoromethyl.
L may be identical of different. The variable n is preferably 1 , 2 or 3.
Particular preference is given to 2-substituted pyrimidines I, wherein one or two radical(s) L is (are) attached to one (or two) of the ortho-position(s) of the phenyl ring system. Moreover, particular preference is given to 2-substituted pyrimidines I, wherein n is 1 , 2 or 3, i. e. the phenyl ring attached to the pyrimidine skeleton carries 1 , 2 or 3 substituents RL which are different from hydrogen.
Particular preference is furthermore given to 2-substituted pyrimidines I, wherein the substituents L are identical or different and selected from the group consisting of:
L halogen, cyano, d-Cβ-alkyl, Ci-C6-alkoxy, -C(=O)-O-A10 or -C(=O)-N(A11)A10 and wherein A10 and A11 are as defined herein, and in particular hydrogen or Ci-C4-alkyl.
Particular preference is likewise given to 2-substituted pyrimidines I, wherein the phenyl group substituted by Ln is B
Figure imgf000018_0001
in which # is the point of attachment to the pyrimidine skeleton and
L1 is fluorine, chlorine, CH3 or CF3, more preferably fluorine or chlorine; L2, L4 independently of one another are hydrogen, CH3 or fluorine, more preferably hydrogen;
L3 is hydrogen, fluorine, chlorine, bromine, cyano, CH3, SCH3, OCH3, SO2CH3, CO-NH2, CO-NHCH3, CO-NHC2H5, CO-N(CHs)2, CS-NH2, CS-NHCH3, CS-N(CHs)2, NH-C(=O)CH3, N(CH3)-C(=O)CH3 Or COOCH3, more preferably hydrogen, fluorine or chlorine, even more preferably hydrogen; and
L5 is hydrogen, fluorine, chlorine or CH3, more preferably fluorine or chlorine.
Furthermore, particularly preferred are 2-substituted pyrimidines of the formula I where
R1 is C2-Cio-alkyl, C2-Cio-alkenyl or C2-Cio-alkynyl, where the aliphatic groups of the radical definitions of R1 for their part may be partially or fully halogenated or may carry one, two, three or four radicals Rv which may be the same or different from each other:
Rv is halogen, cyano, Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, C3-Cβ- cycloalkyl, C4-C6-cycloalkenyl, hydroxyl, d-Cβ-alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyloxy, C4-C6-cycloalkenyloxy, -C(=O)-A1, -C(=O)-O-A1, -C(=O)-N(A2)A1, C(A2X=N-OA1), N(A2)A1, N(A2)-C(=O)-A1, N(A3)-C(=O)-N(A2)A1, S(=0)m-A1, S(=O)m-O-A1 or S(=O)m-N(A2)A1, it also being possible that two vicinal radicals Rv together are (=0) or (=S);
R2 is halogen, cyano, Ci-C4-alkyl, Ci-C4-alkoxy or Ci-C4-haloalkyl;
R3 has the meanings given in claim 1 but does not carry any group Rwa;
n is 1 , 2 or 3 where at least one substituent L is located in the ortho-position on the phenyl ring and wherein L are identical or different and selected from the group consisting of:
L halogen, cyano, d-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, Ci-Cβ-alkoxy, C2-C10- alkenyloxy, C2-Cio-alkynyloxy, nitro, -C(=O)-O-A10, -C(=O)-N(A11)A10, -C(=S)-N(A11)A10, C(A11X=N-OA10), N(A11)A10, N(A11)-C(=O)-A10 and S(=O)P-A10, where
A10, A11 independently of one another are hydrogen, d-Cε-alkyl, C2-C6- alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl or phenyl, where the organic radicals may be partially or fully halogenated or may be substituted by halogen, cyano and/or Ci-C4-alkoxy; or A10 and A11 together with the atoms to which they are attached are a five- or six-membered partially unsaturated or aromatic heterocycle which comprises one, two, three or four heteroatoms selected from the group consisting of O, N and S;
and where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of L for their part may be partially or fully halogenated or may carry one, two, three or four radicals RL, which may be the same or different from each other.
More preferred are 2-substituted pyrimidines of the formula I (embodiment A) where
n is 1 , 2 or 3, where at least one substituent L is located in the ortho-position on the phenyl ring;
L is halogen, cyano, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-C6-alkoxy, -C(=O)-O-A1 and - C(=O)-N(A11)A10 and wherein A10 and A11 are as defined herein, and in particular hydrogen or Ci-C4-alkyl; L is more preferably chlorine, fluorine, CH3 or CF3;
R1 is C4-C8-alkyl or C4-C8-haloalkyl, preferably C4-C6-alkyl, which in each case is branched but preferably not branched in the α-position (e. g. branched in the β- or γ-position), and which is unsubstituted or may carry one or two, especially one radical Rv selected from the group consisting of hydroxyl and Ci-C4-alkoxy such as methoxy or ethoxy, e. g. (2-methyl)-but-1-yl, (3-methyl)-but-1-yl, (2,2-dimethyl)-but-1-yl, (2,3-dimethyl)-but-1-yl, (3,3-dimethyl)-but-1-yl, 2-hydroxy- (3-methyl)-but-1 -yl, 3-hydroxy-(3-methyl)-but-1 -yl, 4-hydroxy-(3-methyl)-but-1 -yl,
2-hydroxy-(2-methyl)-but-1 -yl, 3-hydroxy-(2-methyl)-but-1 -yl, 4-hydroxy-(2-methyl)-but-1-yl and (2-methyl)-prop-1-yl, more preferably (2-methyl)-but-1-yl, 2-hydroxy-(3-methyl)-but-1-yl and (2-methyl)-prop-1-yl;
R2 is halogen, cyano, Ci-C4-alkyl, Ci-C4-alkoxy or Ci-C4-haloalkyl, in particular chlorine, fluorine, cyano, methyl, ethyl, methoxy or ethoxy;
R3 is selected from the group consisting of cyano, C(=O)NHCH3, C(=NOCH3)NH2,
C(=NOH)NH2, C(=NOCH3)CH3, C(=NOH)CH3, NH(C(=O)OCH3), N(C(=O)CH3)-OCH3, ON(=C(CH3)2), NH(C(=O)CH3), C(=O)NH2, C(=S)NH2,
C(=O)-O(CH3), C(=O)-O(CH2CH3), C(=O)-O(CH2CH2CH3) and C(=O)-OCH(CH3)2, with most preference given to R3 being selected from the group consisting of cyano, C(=NOCH3)NH2, C(=NOH)NH2,C(=O)NH2 and C(=S)NH2.
Likewise preferred are 2-substituted pyrimidines of the formula I (embodiment B) where
n is 1 , 2 or 3, where at least one substituent L is located in the ortho-position on the phenyl ring;
L is halogen, cyano, Ci-C4-alkyl, Ci-C4-haloalkyl, d-Cβ-alkoxy, -C(=O)-O-A1 and - C(=O)-N(A11)A10 and wherein A10 and A11 are as defined herein, and in particular hydrogen or Ci-C4-alkyl; L is more preferably chlorine, fluorine, CH3 or CF3;
R1 is C2-Cs-alkenyl or C2-C8-haloalkenyl, preferably C2-C8-alkenyl, e. g. but-1-en-4-yl
(= but-3-en-1-yl), but-2-en-1-yl, 2-methyl-but-1-enyl, 3-methyl-but-1-enyl, 2- methyl-but-2-en-1-yl and 3-methyl-but-2-en-1-yl, more preferably but-1-en-4-yl and 3-methyl-but-1-enyl;
R2 is halogen, cyano, Ci-C4-alkyl, Ci-C4-alkoxy or Ci-C4-haloalkyl, in particular chlorine, fluorine, cyano, methyl, ethyl, methoxy or ethoxy;
R3 is selected from the group consisting of cyano, C(=O)NHCH3, C(=NOCH3)NH2, C(=NOH)NH2, C(=NOCH3)CH3, C(=NOH)CH3, NH(C(=O)OCH3), N(C(=O)CH3)-OCH3, ON(=C(CH3)2), NH(C(=O)CH3), C(=O)NH2, C(=S)NH2, C(=O)-O(CH3), C(=O)-O(CH2CH3), C(=O)-O(CH2CH2CH3) and C(=O)-OCH(CH3)2, with most preference given to R3 being selected from the group consisting of cyano, C(=NOCH3)NH2, C(=NOH)NH2,C(=O)NH2 and C(=S)NH2.
Likewise preferred are 2-substituted pyrimidines of the formula I (embodiment C) and their salts, where
n is 1 , 2 or 3, where at least one substituent L is located in the ortho-position on the phenyl ring;
L is halogen, cyano, Ci-C4-alkyl, Ci-C4-haloalkyl, Ci-Cβ-alkoxy, -C(=O)-O-A1 and - C(=O)-N(A11)A10 and wherein A10 and A11 are as defined herein, and in particular hydrogen or Ci-C4-alkyl; L is more preferably chlorine, fluorine, CH3 or CF3;
R1 is C3-Ci2-cycloalkyl, C3-Cio-cycloalkenyl, phenyl, or a C-bound heterocycle which may carry an oxygen atom (-O-), an imino nitrogen (=N-) or an amino -(-N(RX)- group as ring member, where Rx is hydrogen or C-i-Cβ-alkyl, and/or where the ring formed may carry one or more, e. g. 1 , 2, 3 or 4, preferably 1 substituent(s) from the group consisting of halogen, d-Cε-alkyl, d-Cε-haloalkyl and oxy-Ci-C3- alkyleneoxy, in particular halogen, d-Cε-alkyl and C-i-Cε-haloalkyl. Amongst these, particular preference is given to compounds I, wherein R1 selected from cyclopentyl, cyclohexyl, pyrrolidin-2-yl and piperidin-2-yl, and which may carry one or two d-Cε-alkyl, preferably Ci-C4-alkyl substituents, e. g. methyl, ethyl, prop-1-yl and prop-2-yl, more preferably Ci-C2-alkyl substituents, e. g. methyl, ethyl, especially methyl;
R2 is halogen, cyano, Ci-C4-alkyl, Ci-C4-alkoxy or Ci-C4-haloalkyl, in particular chlorine, fluorine, cyano, methyl, ethyl, methoxy or ethoxy;
R3 is selected from the group consisting of cyano, C(=O)NHCH3, C(=NOCH3)NH2, C(=NOH)NH2, C(=NOCH3)CH3, C(=NOH)CH3, NH(C(=O)OCH3), N(C(=O)CH3)-OCH3, ON(=C(CH3)2), NH(C(=O)CH3), C(=O)NH2, C(=S)NH2, C(=O)-O(CH3), C(=O)-O(CH2CH3), C(=O)-O(CH2CH2CH3) and
C(=O)-OCH(CH3)2, with most preference given to R3 being selected from the group consisting of cyano, C(=NOCH3)NH2, C(=NOH)NH2,C(=O)NH2 and C(=S)NH2.
In particular with a view to their use as anticancer agents, preference is given to the compounds I of the formulae I.A, I. B, I.C, I. D, I. E, I. F, I.G, I. H, IJ, I. K, I. L, I. M, I.N, I.N, I.O, I.Q, I. R, I.S, IT, I. U, I.V, I.W and I.X as defined below, wherein L, n, R1 and R2 are as defined herein and wherein at least one of the variables, in particular all of the variables L, n, R1 and R2 have the preferred or particulary preferred meanings; specific examples of these compounds being compiled in the tables below. Moreover, the groups mentioned for a substituent in the tables are per se, independently of the combination in which they are mentioned, a particularly preferred embodiment of the substituent in question.
Figure imgf000021_0001
Figure imgf000021_0002
I. D
Figure imgf000022_0001
Figure imgf000023_0001
Figure imgf000023_0002
Table 1
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,6-chloro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 2
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 3
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-dichloro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 4
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,6-methyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A Table 5
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,6-trifluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 6
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-fluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 7
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-methoxycarbonyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 8
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-CN, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 9
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,5-trifluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 10
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-dichloro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 11
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chlorine, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 12
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluorine, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 13 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-difluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 14
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro-4-chloro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A Table 15 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro-4-fluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 16 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,3-difluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 17 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-difluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 18 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,3,4-trifluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 19 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 20 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-dimethyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 21 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl-4-chloro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A Table 22
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro-4-methyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 23
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-dimethyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 24
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN,
LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,6-trimethyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A Table 25
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-cyano, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 26
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-methyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 27
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-methoxycarbonyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 28
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methoxy, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 29
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 30 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methoxycarbonyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 31
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-bromo, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 32
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-cyano, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 33
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro,4-methoxy, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 34
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,3-methyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 35
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-dimethyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 36
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-cyano, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 37
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-bromo, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 38 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-fluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 39
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-methoxy, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 40
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-methoxycarbonyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 41
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-dimethyl,4-bromo, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 42
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-bromo, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 43
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-methoxy, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 44
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,5-methyl, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 45
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is pentafluoro, R2 is methyl and R1 for a compound corresponds in each case to one row of Table A
Table 46 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,6-chloro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 47
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 48
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-dichloro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 49
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,6-methyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 50
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,6-trifluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 51
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-fluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 52
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-methoxycarbonyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 53
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-CN, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 54 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,5-trifluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 55
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-dichloro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 56
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 57
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 58
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-difluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 59
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro-4-chloro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 60
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro-4-fluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 61
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,3-difluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 62 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-difluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 63
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,3,4-trifluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 64
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 65
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-dimethyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 66
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl-4-chloro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 67
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro-4-methyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 68
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-dimethyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 69
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,6-trimethyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 70 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-cyano, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 71
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-methyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 72
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-methoxycarbonyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 73
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methoxy, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 74
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 75
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methoxycarbonyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 76
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-bromo, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 77
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-cyano, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 78 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro,4-methoxy, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 79
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,3-methyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 80
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-dimethyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 81
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-cyano, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 82
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-bromo, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 83
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-fluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 84
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-methoxy, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 85
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-methoxycarbonyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 86 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-dimethyl,4-bromo, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 87
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-bromo, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 88
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-methoxy, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 89
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,5-methyl, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 90
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is pentafluoro, R2 is chloro and R1 for a compound corresponds in each case to one row of Table A
Table 91
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,6-chloro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 92
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 93
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-dichloro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 94 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,6-methyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 95
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,6-trifluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 96
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-fluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 97
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-methoxycarbonyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 98
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-CN, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 99
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,5-trifluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 100
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-dichloro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 101
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 102 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 103
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-difluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 104
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro-4-chloro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 105
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro-4-fluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 106
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,3-difluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 107
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-difluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 108
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,3,4-trifluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 109
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 110 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-dimethyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 11 1
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl-4-chloro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 112
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro-4-methyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 113
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-dimethyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 114
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,6-trimethyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 115
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-cyano, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 116
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-methyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 117
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-methoxycarbonyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 118 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methoxy, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 119
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 120
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methoxycarbonyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 121
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-bromo, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 122
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-cyano, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 123
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro,4-methoxy, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 124
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,3-methyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 125
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-dimethyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 126 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-cyano, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 127
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-bromo, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 128
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-fluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 129
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-methoxy, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 130
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-methoxycarbonyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 131
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-dimethyl,4-bromo, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 132
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-bromo, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 133
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-methoxy, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 134 Compounds of the formulae I .A, LB, I.C, I.D, I.E, I.F, I.G, I.H, I.J, I.K, I.L, I.M, I.N, I.N, 1.0, I.Q, I. R, I.S, IT, I. U, I.V, I.W and I.X, in which Ln is 2-fluoro,5-methyl, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 135
Compounds of the formulae I. A, I. B, I.C, I.D, I.E, I.F, I.G, I.H, I.J, I.K, I.L, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is pentafluoro, R2 is methoxy and R1 for a compound corresponds in each case to one row of Table A
Table 136
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,6-chloro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 137
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 138
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-dichloro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 139
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,6-methyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 140
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,6-trifluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 141
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-fluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 142 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-methoxycarbonyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 143
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,4-CN, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 144
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,5-trifluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 145
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-dichloro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 146
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 147
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 148
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-difluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 149
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro-4-chloro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 150 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro-4-fluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 151
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,3-difluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 152
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-difluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 153
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,3,4-trifluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 154
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 155
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4-dimethyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 156
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl-4-chloro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 157
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro-4-methyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 158 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-dimethyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 159
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,4,6-trimethyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 160
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-cyano, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 161
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-methyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 162
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro-4-methoxycarbonyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 163
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methoxy, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 164
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 165
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-methoxycarbonyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A Table 166
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-bromo, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 167
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-chloro,4-cyano, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 168
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,6-difluoro,4-methoxy, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 169
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-fluoro,3-methyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 170
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2,5-dimethyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 171
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-cyano, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 172
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-bromo, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 173
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-fluoro, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 174 Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-methoxy, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 175
Compounds of the formulae LA, LB, LC, LD, LE, LF, LG, LH, LJ, LK, LL, LM, LN, LN, LO, LQ, LR, LS, LT, LU, LV, LW and LX, in which Ln is 2-methyl,4-methoxycarbonyl, R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 176
Compounds of the formulae LA, LB, LC, LD, LE1 LF1 LG, LH1 LJ1 LK1 LL1 LM1 LN1 LN1 LO1 LQ1 LR1 LS1 LT1 LU1 LV1 LW and LX1 in which Ln is 215-dimethyl,4-bromo1 R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 177
Compounds of the formulae LA1 LB1 LC1 LD1 LE1 LF1 LG1 LH1 LJ1 LK1 LL1 LM1 LN1 LN1 LO1 LQ1 LR1 LS1 LT1 LU1 LV1 LW and LX1 in which Ln is 2-fluoro,4-bromo1 R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 178
Compounds of the formulae LA1 LB1 LC1 LD1 LE1 LF1 LG1 LH1 LJ1 LK1 LL1 LM1 LN1 LN1 LO1 LQ1 LR1 LS1 LT1 LU1 LV1 LW and LX1 in which Ln is 2-fluoro,4-methoxy1 R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 179
Compounds of the formulae LA1 LB1 LC1 LD1 LE1 LF1 LG1 LH1 LJ1 LK1 LL1 LM1 LN1 LN1 LO1 LQ1 LR1 LS1 LT1 LU1 LV1 LW and LX1 in which Ln is 2-fluoro,5-methyl1 R2 is cyano and R1 for a compound corresponds in each case to one row of Table A
Table 180
Compounds of the formulae LA1 LB1 LC1 LD1 LE1 LF1 LG1 LH1 LJ1 LK1 LL1 LM1 LN1 LN1 LO1 LQ1 LR1 LS1 LT1 LU1 LV1 LW and LX1 in which Ln is pentafluoro, R2 is cyano
Table A
Figure imgf000045_0001
Figure imgf000046_0001
Figure imgf000047_0001
Figure imgf000048_0001
Figure imgf000049_0001
Figure imgf000050_0001
Figure imgf000051_0001
Figure imgf000052_0001
Figure imgf000053_0001
Figure imgf000054_0001
Figure imgf000055_0001
Figure imgf000056_0001
The 2-substituted pyrimidines of the formula I, in particular the compounds of the formulae I .A, I.J, I. K and I. P effectively inhibit growth and/or progeny of tumor cells as can be shown by standard tests on tumor cell lines such as HeLa, MCF-7 and COLO 205. In particular, 2-substituted pyrimidines I show in general IC50 values < 10"6 mol/l (i.e. < 1 μM), preferably IC50 values < 5x10"7 mol/l (i.e. < 500 nM) for cell cycle inhibition in HeLa cells as determined by the test procedure outlined below.
Based on the results of these standard pharmacological test procedures, 2-substituted pyrimidines are useful as agents for treating, inhibiting or controlling the growth and/or progeny of cancerous tumor cells and associated diseases in a subject in need thereof.
Therefore these compounds are useful in therapy of cancer in warm blooded vertebrates, i.e. mammals and birds, in particular human beings but also in other mammals of economic and/or social importance e.g. carnivores such as cats and dogs, swine (pigs, hogs and wild boars), ruminats (e.g. cattle, oxen, sheep, deer, goats, bison) and horses, or bird in particular poultry such as turkeys, chickens, ducks, geese, guinea fowl and the like.
In particular, 2-substituted pyrimidines I are useful in therapy of cancer or cancerous disease including cancer of breast, lung, colon, prostate, melanoma, epidermal, kidney bladder, mouth, larynx, esophagus, stomach, ovary, pancreas, liver, skin and brain.
The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and severity of the condition being treated. However, in general satisfactory results are obtained when the compounds of the invention are administered in amounts ranging from about 0.10 to about 100 mg/kg of body weight per day. A preferred regimen for optimum results would be from about 1 mg to about 20 mg/kg of body weight per day and such dosage units are employed that a total of from about 70 mg to about 1400 mg of the active compound for a subject of about 70 kg of body weight are administered in a 24 hour period.
The dosage regimen for treating mammals may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. A decidedly practical advantage is that these active compounds may be administered in any convenient manner such as by the oral, intravenous, intramuscular or subcutaneous routes. The active compounds may be orally administered, for example, with an inert diluent or with an assimilable edible carrier, or they may be enclosed in hard or soft shell gelatine capsules, or they may be compressed into tablets or they may be incorporated directly with the food of the diet. For oral therapeutic administration, these active compounds may be incorporated with excipients and used in the form of ingestible tablets, buccal tablets, troches, capsules, elixirs, suspensions, syrups, wafers and the like. Such compositions and preparations should contain at least 0.1 % of active compound. The percentage of the compositions and preparations may, of course, be varied and may conveniently be between about 2% to about 60% of the weight of the unit. The amount of active compound in such therapeutically useful compositions is such that a suitable dosage will be obtained. Preferred compositions or preparations according to the present invention are prepared so that an oral dosage unit form contains between 10 and 1000 mg of active compound.
The tablets, troches, pills, capsules and the like may also contain the following: a binder such as gum tragacanth, acacia, corn starch or gelatine; excipients such as dicalcium phosphate; a disintegrating agent such as corn starch, potato starch, alginic acid and the like; a lubricant such as magnesium stearate; and a sweetening agent such as sucrose, lactose, or saccharin may be added or a flavoring agent such as peppermint, oil of wintergreen or cherry flavoring. When the dosage unit form is a capsule, it may contain, in addition to materials of the above type, a liquid carrier. Various other materials may be present as coatings or to otherwise modify the physical form of the dosage unit. For instance, tablets, pills or capsules may be coated with shellac, sugar or both. A syrup or elixir may contain the active compound, sucrose, as a sweetening agent, methyl and propylparabens as preservatives, a dye and flavoring such as cherry or orange flavor. Of course, any material used in preparing any dosage unit form should be pharmaceutically pure and substantially non-toxic in the amounts used. In addition, these active compounds may be incorporated into sustained-release preparations and formulations.
These active compounds may also be administered parenterally or intraperitoneal^. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols, and mixtures thereof in oils. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms. The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be prepared against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion medium containing, for example, water, ethanol, polyol (e.g. glycerol, propylene glycol and liquid poly-ethylene glycol), suitable mixtures thereof, and vegetable oils.
The following examples 1-1 to I-7 given in table B are representative compounds of this invention which are useful as anticancer agents.
Table B: Active compounds
Figure imgf000058_0001
Figure imgf000058_0002
*) m.p. = melting point Measurement of the cell cycle inhibition in HeLa cells - test procedure:
HeLa B cells are grown in DMEM (Life Technologies Cat No 21969-035) supplemented with 10% Fetal Calf Serum (FCS, Life Technologies Cat No 10270-106) in 180 cm2 Flasks at 37°C, 92% humidity and 7% CO2.
Cells are seeded at 5x104 cells per well in a 24-well plate. Twenty hours later the compounds are added such that the final concentration is 1 x10"6, 3.3x10"7, 1.1x10"7, 3.7x10"8, 1.2x10"8 and 1 x10"9 M in a final volume of 500 μl. DMSO alone is added to 6 wells as a control. Cells are incubated with the compounds as above for 20 h. Then cells are observed under the microscope to check for cell death, and the 24-well plate is then centrifuged at 1200 rpm for 5 min at 200C, acceleration position 7 and break position 5 (Eppendorf centrifuge 5804R). The supernatant is removed and the cells are lysed with 0.5 ml RNase Buffer (10 mM NaCitrate, 0.1 % Nonidet NP40, 50 μg/ml
RNase, 10 μg/ml Propidium iodide) per well. The plates are then incubated for at least 30 min in the dark at RT and the samples then transferred to FACS tubes. Samples are measured in a FACS machine (Beckton Dickinson) at the following settings:
Instrument Settings of the FACS Calibur: Run Modus: high
Parameter Voltage Amp Gain Mode
FSC E01 2,5 Hn
SSC 350 1 Hn
Fl 1
Fl 2 430 2 Hn
Fl 3
FI 2 - A — 1 Hn
Fl 2 - W — 3 Hn
DDM Parameter Fl 2
The ratio of cells in Go/Gi-phase to G2/M phase is calculated and compared to the value for the controls (DMSO) only. Results are given in table C as the IC50 value calculated from the concentration curve plotted against the cell cycle ratio and indicate the compound concentration at which 50% of cells are in cell cycle arrest after treatment with the compound.
Test on other cell lines (MCF-7 and COLO 205) were done in the same way except that they were incubated with the growth medium recommended by the American Tissue Culture collection for that cell type. Table C
Figure imgf000060_0001

Claims

We claim:
1. 2-substituted 5-phenylpyrimidines of the formula I and their pharmaceutically acceptable salts for use in therapy:
Figure imgf000061_0001
in which the indices and the substituents are as defined below:
R1 is C2-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, C3-Ci2-cycloalkyl, C3-Ci0- cycloalkenyl, phenyl or a five- to ten-membered saturated, partially unsaturated or aromatic heterocycle which is attached via carbon and which contains one, two, three or four heteroatoms selected from the group consisting of O, N and S; where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of R1 for their part may be partially or fully halogenated or may carry one, two, three or four radicals Rv, which may be the same or different from each other:
Rv is halogen, cyano, d-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, C3-Cβ- cycloalkyl, C4-C6-cycloalkenyl, hydroxyl, d-Cβ-alkoxy, C2-Ci0- alkenyloxy, C2-Ci0-alkynyloxy, C3-C6-cycloalkyloxy, C4-C6- cycloalkenyloxy, -C(=O)-A1, -C(=O)-O-A1, -C(=O)-N(A2)A1, C(A2)(=N-OA1), N(A2JA1, N(A2)-C(=O)-A1, N(A3)-C(=O)-N(A2)A1, S(=0)m-A1, S(=0)m-0-A1 or S(=O)m-N(A2)A1, it also being possible that two vicinal radicals Rv together are (=0), (=S) or (=N-OA1), or Rv is phenyl, where the phenyl moiety may carry one, two or three radicals which may be the same or different from each other and which are selected from the group consisting of: halogen, Ci-Cβ-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C6-cycloalkyl, Ci-C6-haloalkyl, CrC6- alkoxy, cyano, nitro, -C(=O)-A, C(=O)-O-A, -C(=O)-N(A')A, C(A')(=N-OA) and N(A')A; where
m is 0, 1 or 2;
A1, A2, A3, A and A' independently of one another are hydrogen, d-Ce-alkyl, C2-C6-alkenyl, C2-C6-alkynyl, C3-C8-cycloalkyl,
C3-C8-cycloalkenyl or phenyl, where the organic radicals may be partially or fully halogenated or may be substituted by halogen, nitro, cyanato, cyano and/or Ci-C4-alkoxy; or A1 and A2, or A and A', respectively, together with the atoms to which they are attached are a five- or six-membered saturated, partially unsaturated or aromatic heterocycle which comprises one, two, three or four heteroatoms selected from the group consisting of O, N and S;
and where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of Rv for their part may be partially or fully halogenated;
R2 is halogen, cyano, Ci-C4-alkyl, C2-C4-alkenyl, C2-C4-alkynyl, C3-C6- cycloalkyl, Ci-C4-alkoxy, C3-C4-alkenyloxy, C3-C4-alkynyloxy, Ci-Cβ- alkylthio, di-(Ci-C6-alkyl)amino or Ci-Cβ-alkylamino, where the aliphatic and/or alicyclic groups of the radical definitions of R2 for their part may be partially or fully halogenated or may carry one, two, three or four radicals Ru, which may be the same or different from each other:
Ru is halogen, cyano, Ci-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, hydroxyl, Ci-C6-alkoxy, Cs-Cβ-cycloalkyl, C2-Cio-alkenyloxy, C2-C10- alkynyloxy, C4-C6-cycloalkenyl, Cs-Cβ-cycloalkyloxy, C4-C6- cycloalkenyloxy, -C(=O)-A4, -C(=O)-O-A4, -C(=O)-N(A5)A4, C(A5)(=N-OA4), N(A5)A4, N(A5)-C(=O)-A4, N(A6)-C(=O)-N(A5)A4, S(=O)q-A4, S(=O)q-O-A4 or S(=O)q-N(A5)A4, it also being possible that two vicinal radicals Ru together are (=0) or (=S), where
q is O, 1 or 2;
A4, A5 and A6 independently of one another have the meanings of
A1, A2 and A3 as defined above;
and where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of Ru for their part may be partially or fully halogenated or may carry one, two or three radicals Rua, which may be the same or different from each other and which have the meanings of Ru as defined above;
R3 is selected from the group consisting of cyano, C(=Z)ORa, C(=Z)NRzRb, C(=Z)NRz-ORa, C(=Z)NRa-NRzRb, C(=Z)Ra, ON(=CRaRb), O-C(=Z)Ra,
NRa(C(=Z)Rb), NRa(C(=Z)ORb), NRa(C(=Z)-NRzRb), NRa(N=CRcRb), NRa-NRzRb, NRz-ORa, and the radicals of the formulae R3a and R3b
Figure imgf000062_0001
where
Z is O, S, NRa1, NORa1 or N-NRz1Rc1;
Ra, Ra1, Rb, Rc, Rc1 independently of one another are hydrogen, Ci-Cβ- alkyl, C2-C6-alkenyl, C2-C6-alkynyl, Cs-Cβ-cycloalkyl or C4-C6- cycloalkenyl;
Rb1 has the meanings of Rb as defined above, except for hydrogen; and
Rz, Rz1 independently of one another have the meanings of Ra as defined above and may additionally be -CO-Ra2, where Ra2 has the meanings of Ra as defined above;
where the aliphatic and/or alicyclic groups of the radical definitions of Ra, Ra1, Rb, Rb1, Rc, Rc1, Rz and Rz1 for their part may be partially or fully halogenated or may carry one, two, three or four groups R1, which may be the same or different from each other:
R1 is halogen, cyano, Ci-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, Ci-Cβ- alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyl, C3-C6- cycloalkenyl, Cs-Cβ-cycloalkoxy or Cs-Cβ-cycloalkenyloxy,
and where two of the radicals Ra, Ra1, Rb, Rb1, Rc, Rc1, Rz or Rz1 together with the atoms, to which they are attached, may form a five-, six- or seven- membered saturated, partially unsaturated or aromatic heterocycle which comprises one, two, three or four heteroatoms selected from the group consisting of O, N and S,
and where # in the formulae R3a and R3b indicates the atom which is bond to the 2-position of the pyrimidine ring
x is O or i ;
Re, Rf, R9, Re# independently of one another are hydrogen, d-Cε-alkyl, C2-C8-alkenyl, C2-C8-alkynyl, Cs-Cβ-cycloalkyl, C4-C6-cycloalkenyl,
Rf, Ra together with the nitrogen atom to which they are attached may have the meaning Re-Z-C(Rh)=N;
Q is oxygen or N-Re#; Q' is C(H)-Rk, C-Rk , N-N(H)-Re# or N-Re#;
ilii may be a double bond or a single bond;
Rh, Rk have the same meanings as Re and may additionally be halogen or cyano; or
Rh together with the carbon to which it is attached may be a carbonyl group;
where the aliphatic, alicyclic or aromatic groups of the radical definitions of Re, Re#, Rf, R9, Rh or Rk for their part may be partially or fully halogenated or may carry one to four groups Rw, which may be the same or different from each other:
Rw is halogen, cyano, d-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, d-Cβ-alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyl, C3-C6-cycloalkenyl, Cs-Cβ-cycloalkoxy, Cs-Cβ-cycloalkenyloxy, and where two of the radicals Rf, Rs, Re or Re# together with the atoms to which they are attached may form a five- or six-membered saturated, partially unsaturated or aromatic heterocycle which contains one to four heteroatoms from the group consisting of O, N and S;
n is 1 , 2, 3, 4 or 5;
L are independently of each other selected from halogen, cyano, cyanato (OCN), Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, d-Ce-alkoxy, C2-Ci0- alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyl, C4-C6-cycloalkenyl, C3-C6- cycloalkyloxy, C4-C6-cycloalkenyloxy, nitro, -C(=O)-A10, -C(=O)-O-A10, - C(=O)-N(A11)A10, -C(=S)-N(A11)A10, -C(=NA11)-SA10, C(A11)(=N-OA10),
N(A11)A10, N(A11)-C(=O)-A10, N(A12)-C(=O)-N(A11)A10, S(=O)P-A10, S(=O)p-O-A10 or S(=O)p-N(A11)A10, where
p is O, 1 or 2;
A10, A11, A12 independently of one another have the meanings of A1, A2 and A3 as defined above;
where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of L for their part may be partially or fully halogenated or may carry one, two, three or four radicals RL, which may be the same or different from each other: RL is halogen, cyano, Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, hydroxyl, Ci-C6-alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, C3-C6- cycloalkyl, C4-C6-cycloalkenyl, Cs-Cβ-cycloalkyloxy, C4-C6- cycloalkenyloxy, -C(=O)-A13, -C(=O)-O-A13, -C(=O)-N(A14)A13, C(A14X=N-OA13), N(A14)A13, N(A14)-C(=O)-A13,
N(A15)-C(=O)-N(A14)A13, S(=O)s-A13, S(=O)S-O-A13 or S(=O)s-N(A14)A13; it also being possible that two vicinal radicals RL together are (=0) or (=S), where
s is 0, 1 or 2; and
A13, A14 and A15 independently of one another have the meanings of A1, A2 and A3 as defined above;
and where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of RL for their part may be partially or fully halogenated or may carry one, two, three or four groups RLA, which may be the same or different from each other and which have the meanings of RL as defined above.
2. The compounds according to claim 1 , where
R1 is C2-Cio-alkyl, C2-Cio-alkenyl or C2-Cio-alkynyl where the aliphatic groups of the radical definitions of R1 for their part may be partially or fully halogenated or may carry one, two, three or four radicals Rv which may be the same or different from each other:
Rv is halogen, cyano, Ci-Cio-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, C3-C6- cycloalkyl, C4-C6-cycloalkenyl, hydroxyl, Ci-Cβ-alkoxy, C2-C10- alkenyloxy, C2-Cio-alkynyloxy, Cs-Cβ-cycloalkyloxy, C4-C6- cycloalkenyloxy, -C(=O)-A1, -C(=O)-O-A1, -C(=O)-N(A2)A1, C(A2X=N-OA1), N(A2)A1, N(A2)-C(=O)-A1, N(A3)-C(=O)-N(A2)A1, S(=0)m-A1, S(=0)m-0-A1 or S(=O)m-N(A2)A1, it also being possible that two vicinal radicals Rv together are (=0), (=S) or (=N-OA1);
R2 is halogen, cyano, Ci-C4-alkyl, Ci-C4-alkoxy or Ci-C4-haloalkyl;
n is 1 , 2 or 3 where at least one substituent L is located in the ortho-position on the phenyl ring;
L is halogen, cyano, d-Cs-alkyl, C2-Cio-alkenyl, C2-Cio-alkynyl, Ci-Cβ-alkoxy, C2-Cio-alkenyloxy, C2-Cio-alkynyloxy, nitro, -C(=O)-O-A10, -C(=O)-N(A11)A10, -C(=S)-N(A11)A10, C(A11)(=N-OA10), N(A11)A10, N(A11)-C(=O)-A10 or S(=O)P-A10, where
A10, A11 independently of one another are hydrogen, d-Cε-alkyl, C2-C6- alkenyl, C2-C6-alkynyl, Cs-Cs-cycloalkyl or phenyl, where the organic radicals may be partially or fully halogenated or may be substituted by halogen, cyano and/or Ci-C4-alkoxy; or A10 and A11 together with the atoms to which they are attached are a five- or six-membered partially unsaturated or aromatic heterocycle which comprises one, two, three or four heteroatoms selected from the group consisting of O, N and S;
and where the aliphatic, alicyclic and/or aromatic groups of the radical definitions of L for their part may be partially or fully halogenated or may carry one, two, three or four radicals RL, which may be the same or different from each other.
3. The compounds according to any of claims 1 or 2, wherein
R3 is selected from the group consisting of cyano, C(=O)NRzRb,
C(=NRa1)NRzRb, C(=NORa1)NRzRb, C(=N-NRz1Rc1)NRzRb, C(=S)NRzRb, C(=O)Ra, C(=NRa1)Ra, C(=NORa1)Ra, C(=N-NRz1Rc1)Ra, C(=O)ORa,
C(=NRa1)ORa, C(=NORa1)ORa, C(=O)NRz-ORa, C(=NRa1)NRz-ORa, C(=NORa1)NRz-ORa, C(=O)NRa-NRzRb, O-C(=O)Ra, O-N(=CRaRb), NRa(C(=O)Rb), NRa(C(=S)Rb), NRa(C(=NRa1)Rb), NRa(C(=NORa1)Rb), NRa(C(=O)ORb), NRa(C(=O)-NRzRb), NRa(C(=NRa1)-NRzRb), NRa(N=CRcRb), NRa-NRzRb and NRz-ORa.
4. The compounds according to claim 3, wherein
R3 is selected from the group consisting of cyano, C(=O)NRzRb, C(=NORa1)NRzRb, C(=S)NRzRb, C(=O)NRz-ORa, C(=NORa1)Ra and
C(=N-NRz1Rc1)Ra.
5. The compounds according to claim 3, in which
R3 is selected from the group consisting of ON(=CRaRb), NRa(C(=O)Rb),
NRa(C(=O)ORb), NRa(N=CRcRb) and NRz-ORa.
6. The compounds according to any of the preceding claims, wherein
R1 is C2-C8-alkyl, C2-C8-haloalkyl, C2-Cs-alkenyl or C2-C8-haloalkenyl, which in each case may carry one or two radicals Rv selected from the group consisting of hydroxyl and Ci-C4-alkoxy.
7. The compounds according to any of the preceding claims, wherein the phenyl group substituted by Ln is given by the formula B
Figure imgf000067_0001
where # is the point of attachment to the pyridine skeleton and
L1 is fluorine, chlorine, CH3 or CF3;
L2, L4 independently of one another are hydrogen, CH3 or fluorine; L3 is hydrogen, fluorine, chlorine, bromine, nitro, cyano, CH3, SCH3, OCH3,
SO2CH3, CO-NH2, CO-NHCH3, CO-NHC2H5, CO-N(CH3)2, CS-NH2, CS-NHCH3, CS-N(CHs)2, NH-C(=O)CH3, N(CH3)-C(=O)CH3 or COOCH3; and
L5 is hydrogen, fluorine, chlorine or CH3.
8. A pharmaceutical composition comprising a 2-substituted 5-phenylpyrimidine compound of the formula I as defined in any of the preceding claims or a pharmaceutically acceptable salt thereof.
9. 2-substituted 5-phenylpyrimidine compounds of the formula I as defined in any of claims 1 to 7 and their pharmaceutically acceptable salts for use in therapy of cancer.
10. A pharmaceutical composition comprising a 2-substituted 5-phenylpyrimidine compound of the formula I as defined in any of claims 1 to 7 or a pharmaceutically acceptable salt thereof.
1 1. The use of 2-substituted 5-phenylpyrimidine compounds of the formula I as defined in any of claims 1 to 7 and their pharmaceutically acceptable salt in therapy of a disease.
12. The use according to claim 11 , wherein the disease is cancer.
13. The use of a 2-substituted 5-phenylpyrimidine compound of the formula I as defined in any of claims 1 to 7 and of their pharmaceutically acceptable salts in the manufacture of a medicament.
14. The use according to claim 13, where the medicament is for the treatment of cancer.
15. The use of a 2-substituted 5-phenylpyrimidine compound of the formula I as defined in any of claims 1 to 7 and of their pharmaceutically acceptable salts for the treatment of cancer in animals, in particular humans.
16. A method for cancer treatment in animals, in particular humans, which comprises administering to the subject in need thereof an effective amount of a 2-substituted 5-phenylpyrimidine compound of the formula I as defined in any of claims 1 to 7 or of their pharmaceutically acceptable salts.
PCT/EP2008/050253 2007-01-11 2008-01-10 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders WO2008084081A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07100426 2007-01-11
EP07100426.1 2007-01-11

Publications (2)

Publication Number Publication Date
WO2008084081A2 true WO2008084081A2 (en) 2008-07-17
WO2008084081A3 WO2008084081A3 (en) 2008-10-09

Family

ID=39103759

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/050253 WO2008084081A2 (en) 2007-01-11 2008-01-10 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders

Country Status (4)

Country Link
AR (1) AR064852A1 (en)
CL (1) CL2008000097A1 (en)
TW (1) TW200836741A (en)
WO (1) WO2008084081A2 (en)

Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919229A (en) * 1973-07-19 1975-11-11 Labaz Pyrimidine derivatives and process for preparing the same
WO2004029204A2 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
WO2004069846A1 (en) * 2003-02-06 2004-08-19 Basf Aktiengesellschaft Pyrimidines, methods for the production thereof, and use thereof
WO2004087678A1 (en) * 2003-04-04 2004-10-14 Basf Aktiengesellschaft 2-substituted pyrimidines
WO2004110453A1 (en) * 2003-06-18 2004-12-23 Pfizer Products Inc. Pyrimidine derivatives as cannabinoid receptor ligands
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
WO2005030216A1 (en) * 2003-09-24 2005-04-07 Wyeth Holdings Corporation 5-arylpyrimidines as anticancer agents
WO2005070899A1 (en) * 2004-01-23 2005-08-04 Bayer Cropscience Ag 5-phenylpyrimidines and their use as microbicides
WO2006079556A2 (en) * 2005-01-31 2006-08-03 Basf Aktiengesellschaft Substituted 5-phenyl pyrimidines i in therapy
WO2008015250A1 (en) * 2006-08-02 2008-02-07 Basf Se Pyrimidine compounds for combating pathogenic fungi and cancer

Patent Citations (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3919229A (en) * 1973-07-19 1975-11-11 Labaz Pyrimidine derivatives and process for preparing the same
WO2004029204A2 (en) * 2002-09-27 2004-04-08 Merck & Co., Inc. Substituted pyrimidines
WO2004069846A1 (en) * 2003-02-06 2004-08-19 Basf Aktiengesellschaft Pyrimidines, methods for the production thereof, and use thereof
WO2004087678A1 (en) * 2003-04-04 2004-10-14 Basf Aktiengesellschaft 2-substituted pyrimidines
WO2004110453A1 (en) * 2003-06-18 2004-12-23 Pfizer Products Inc. Pyrimidine derivatives as cannabinoid receptor ligands
WO2005030216A1 (en) * 2003-09-24 2005-04-07 Wyeth Holdings Corporation 5-arylpyrimidines as anticancer agents
US20050070712A1 (en) * 2003-09-26 2005-03-31 Christi Kosogof Pyrimidine derivatives as ghrelin receptor modulators
WO2005070899A1 (en) * 2004-01-23 2005-08-04 Bayer Cropscience Ag 5-phenylpyrimidines and their use as microbicides
WO2006079556A2 (en) * 2005-01-31 2006-08-03 Basf Aktiengesellschaft Substituted 5-phenyl pyrimidines i in therapy
WO2008015250A1 (en) * 2006-08-02 2008-02-07 Basf Se Pyrimidine compounds for combating pathogenic fungi and cancer

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ACTON ET AL: "Characterization and antimalarial activity of four acetylated pyrimethamines" HETEROCYCLES, ELSEVIER SCIENCE PUBLISHERS B.V. AMSTERDAM, NL, vol. 14, no. 4, 1980, pages 471-476, XP009096789 ISSN: 0385-5414 *
CARRAZ G ET AL: "Effects of pyrimethamine amidification by dipropylacetic acid. 1. Decrease of toxicity, persistence of activity on Plasmodium berghei, increase of activity on Toxoplasma Rh (Sabin)" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 9, no. 6, 1974, pages 658-659, XP009096848 ISSN: 0223-5234 *
COATS E A ET AL: "CORRELATION ANALYSIS OF PYRIMIDINE FOLIC ACID ANTAGONISTS AS ANTIBACTERIAL AGENTS .L" EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, EDITIONS SCIENTIFIQUE ELSEVIER, PARIS, FR, vol. 14, no. 3, May 1979 (1979-05), pages 261-270, XP000985014 ISSN: 0223-5234 *

Also Published As

Publication number Publication date
WO2008084081A3 (en) 2008-10-09
TW200836741A (en) 2008-09-16
AR064852A1 (en) 2009-04-29
CL2008000097A1 (en) 2008-05-16

Similar Documents

Publication Publication Date Title
JP6771469B2 (en) Anthelmintic compounds, compositions and how to use them
JP4769742B2 (en) Pharmaceutical composition having a carboxylic acid derivative
WO2008080937A1 (en) 2-substituted pyrimidines i in therapy
JP7272709B2 (en) 3-aryloxyl-3-5-membered heteroaryl-propylamine compounds and uses thereof
PT2277865E (en) Phenyl-substituted 6-ring nitrogen-heterocycles as microtubule polymerisation inhibitors
US20220119375A1 (en) 3-aryloxy-3-aryl-propylamine compound and uses thereof
KR20100126464A (en) Crystal form of phenylamino pyrimidine derivatives
US20220153685A1 (en) Small molecule ampk activators
FI67686B (en) PROCEDURE FOR THE FRAMEWORK OF THERAPEUTIC ANIMAL PRODUCTS
WO2008080938A1 (en) Use 2-substituted pyridines for cancer treatment
WO2006079556A2 (en) Substituted 5-phenyl pyrimidines i in therapy
US20220213075A1 (en) 3-aryloxy-3-five-membered heteroaryl propylamine compound, and crystal form and use thereof
KR20200024120A (en) Use of morphinan derivatives for the treatment of opioid δ receptor agonist related diseases
KR101208956B1 (en) Erlotinib dichloroacetate and anti-cancer agent comprising the same
KR20000076252A (en) Novel carboxylic acid derivatives, their preparation and use in treating cancer
WO2008084081A2 (en) 2-substituted 5-phenylpyrimidines for the treatment of proliferative disorders
EP1611126A1 (en) Chromenone indoles
EP3195867A1 (en) Pyrimidine compounds inhibiting the formation of nitric oxide and prostaglandin e2, method of production thereof and use thereof
CN107304180B (en) Benzamide derivative, preparation method and medical application thereof
KR20170088882A (en) Pharmaceutical composition having bicyclic nitrogen-containing aromatic heterocyclic amide compound as active component
KR100916716B1 (en) Novel 3-chloro-5-substituted-quinoxaline-2-amine derivatives and pharmaceutically acceptable salt thereof, method for preparation, therapeutic agent for antiinflammatory disease induced by spc activity containing 3-chloro-5-substituted-quinoxaline-2-amine derivatives as an effective ingredient
KR20170088881A (en) Pharmaceutical composition having bicyclic nitrogen-containing aromatic heterocyclic amide compound as active component
CZ324199A3 (en) Medicament for inhibiting growth of solid tumor in human and process for preparing thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08701399

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08701399

Country of ref document: EP

Kind code of ref document: A2